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Background and aim: Patients with eosinophilic esophagitis (EoE) usually present with 
dysphagia and food impaction events. A subgroup of EoE patients do not experience 
symptomatic improvement despite the use of corticosteroid therapy. The effectiveness of an 
empiric six-food elimination diet (SFED) has been demonstrated in children and adults 
suffering from EoE, but this diet has not yet been tested in a Norwegian cohort. We aimed to 
assess the effects of the SFED on esophageal symptoms and histopathology in Norwegian 
adult patients with EoE. Subsequently, systematic reintroduction of the eliminated foods was 
carried out to identify potential dietary triggers of EoE.  
Methods: A total of 10 adults with EoE underwent upper endoscopies with esophageal 
biopsies, blood tests, skin-prick tests for dietary allergens and aeroallergens, impedance 
manometry and ambulatory pH-monitoring. After following the SFED for a minimum of six 
weeks, the following procedures were repeated on each patient: endoscopy with biopsies, 
blood test, and impedance manometry. Symptomatic responders, defined by decreased 
frequency of dysphagia episodes from baseline to post-SFED, underwent sequential 
reintroduction of each eliminated food at 14-day intervals. Symptom scores and health-related 
quality of life (HRQOL) before and after the SFED were assessed by the Eosinophilic 
Esophagitis Activity Index (EEsAI) and 36-Item Short Form Survey (SF-36), respectively. 
Results: The median peak eosinophil count in esophageal biopsies decreased from  
80 eos/HPF before to 10.5 eos/HPF after the SFED (p=0.0078). Overall symptom score 
measured by the EEsAI did not change significantly from baseline (mean 44.9) to after the 
SFED (mean 30.7). When assessed through patient consultations and change in dysphagia 
frequency from baseline to after the SFED, seven patients reported improvement in 
esophageal symptoms. The most common trigger food identified during reintroduction was 
wheat, and SPT did not effectively predict trigger foods. Notable changes in esophageal 
peristalsis were not evident, as assessed by impedance manometry. There was no significant 
change in HRQOL before and after the SFED, as measured by the SF-36. 
Conclusion: The SFED effectively reduced histopathological signs and improved esophageal 
symptoms of EoE in adult patients. Sequential reintroduction identified trigger foods, 
corroborating the role of dietary allergens in EoE pathogenesis. The empiric SFED represents 
an important alternative treatment modality to corticosteroids in adults, although further 
research is warranted on its long-term effects on EoE disease activity.      
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The term ‘esophageal disease’ encompasses a wide range of conditions affecting the anatomy, 
physiology and motility of the esophagus (1). Among the most prevalent esophageal diseases 
are gastroesophageal reflux disease (GERD), Barrett’s esophagus, esophageal 
adenocarcinoma, as well as eosinophilic esophagitis (EoE) (1). 
 
EoE has been classified as an eosinophilic gastrointestinal disorder (EGID), a term 
collectively referring to EoE, eosinophilic gastroenteritis (EGE) and eosinophilic colitis (EC). 
In EoE, eosinophilic inflammation is limited to the esophagus, whereas the entire 
gastrointestinal tract may be affected in EGE or EC (2). EoE is a relatively recently identified 
chronic immune-mediated disease of the esophagus (3). Histologically, EoE is characterized 
by eosinophilic influx into the esophageal epithelium, and clinically by symptoms related to 
esophageal dysfunction (4). 
 
1.1 Disease definition 
EoE was initially recognized as a distinct clinical entity in the early 1990s (5). The first 
consensus recommendations for the diagnosis and management of EoE were written in 2007, 
whereas a revised version was published in 2011, presenting the first formal definition of the 
disease (6). At present, EoE is defined as a clinicopathological disorder that meets the 
following requirements (7): 
 
(1) Presence of symptoms related to esophageal dysfunction, e.g. dysphagia, food impaction, 
chest pain or heartburn 
(2) With certain exceptions, esophageal biopsy must demonstrate 15 or more eosinophils per 
high-power field (eos/HPF) 
(3) Unresponsiveness to acid suppression therapy using proton-pump inhibitor (PPI) 
(4) Mucosal eosinophilia should be isolated to the esophagus, and secondary causes of 
esophageal eosinophilia (EE) should be excluded, e.g. EGE, infection, drug hypersensitivity, 
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1.2 History of eosinophilic esophagitis 
 
1.2.1 Eosinophilia linked to GERD 
Eosinophils are present in most parts of the gastrointestinal mucosa, though they do not 
inhabit the normal esophageal epithelium (8). There are reports from the 1960s and 1970s that 
describe cases that could have potentially been identified as EoE today (9). Esophageal 
biopsies from these patients showed basal zone hyperplasia, papillary lengthening and 
intraepithelial eosinophilia. Despite being uncommon in GERD, these histological findings 
were interpreted as GERD-associated complications (9). However, it remained unclear why 
acid reflux only altered the esophageal epithelium in certain patients. Regardless of the 
inconsistencies, the association of GERD with esophageal eosinophilia persisted for several 
years (8). 
 
1.2.2 Eosinophilia linked to EGE 
While GERD-related eosinophilia was considered the main cause of esophagitis for years, 
multiple case series started to report clinical characteristics that differed from the typical 
clinical features associated with GERD (8). In 1978 Landres et al. described a case of  
vigorous achalasia in a subject with marked smooth muscle hypertrophy and esophageal 
eosinophilia (10). It was suggested that this subject represented a subtype of EGE that could 
potentially predispose to esophageal achalasia. However, eosinophilic infiltration was known 
to be unusual in tissues affected by motor disorders such as achalasia, making the proposed 
theory subject to debate (8). 
 
In 1981, Picus and Frank presented a case of progressive dysphagia in a 16-year-old boy (11). 
Endoscopy results showed proximal dilation of the esophagus as well as several 1 mm 
nodular filling defects close to a stricture. Radiological studies revealed narrowing of the 
lumen, wall rigidity as well as elevated levels of circulating eosinophils. Yet again, these 
findings were considered to represent a variant of EGE (12). This was followed by new case 
reports from Munch et al. in 1982 (13), and Matzinger and Daneman in 1983 (14). They 
described isolated incidents of esophageal eosinophilia accompanied by dysphagia in patients 
who allegedly suffered from EGE (12). In 1985, Feckzo et al. (15) described three cases of 
esophageal eosinophilia, out of which two subjects suffered from EGE. Among the three 
patients, two developed submucosal fibrosis, which eventually led to esophageal stricture 
(15). However, these reports did not include any etiology, and concluded that reflux was 
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involved. In retrospect, these were presumably cases of EoE (12). In 1985, Lee published a 
more extensive report of 11 patients with mucosal esophageal eosinophilia (16). This cohort 
consisted of patients with an average age of 14.6 years, who experienced reflux symptoms 
alongside low eosinophil density. In retrospect, these patients likely suffered from GERD 
(12). 
 
1.2.3 Recognition of EoE 
Characterization of EoE as a separate disease entity took place in 1993, when Attwood et al. 
published a case series of 12 adult patients affected by dysphagia (17). These patients 
exhibited normal pH monitoring, as well as high eosinophil density in the esophageal mucosa 
(>20 eos/HPF). Notably, patients diagnosed with GERD had a mean eosinophil density of  
3.3 eos/HPF. Within the cohort, seven patients suffered from food hypersensitivity, and all 
were dependent on advanced intervention such as dilatation and/or steroids in one case (17). 
Thereafter, Straumann et al. published a case series of 10 patients with acute recurrent 
dysphagia observed over a four-year span. Endoscopy results revealed distinct changes and 
elevated concentrations of eosinophils in esophageal epithelia, managed with antihistamines 
and systemic steroids (18).  
 
The first pediatric work on EoE was published by Kelly et al. in 1995 (19). They described 10 
children who had been diagnosed with EoE, based on clinical observations and histological 
examination. Six of the children had received antireflux treatment without resolution of 
symptoms, whereas two of the children had been subject to fundoplication. All 10 children 
responded well to amino acid formulas, indicating an allergic etiology for EoE (19). 
  
Between 1995 and 2005, there was a substantial increase in clinical studies and the 
recognition of EoE (20). In 2007, consensus guidelines on the diagnosis and management of 
EoE were formulated by a multidisciplinary group, known as the First International 
Gastrointestinal Eosinophil Research Symposium Subcommittees (21). This publication 
further facilitated the identification of EoE and led to increased awareness of the disease (20).  
 
1.3 Epidemiology and risk factors 
Cases of EoE have been reported in children and adults from all continents, with the highest 
burden of disease being recognized in North America, Western Europe and Australia (22).  
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Several studies have aimed to address epidemiological questions in EoE, including 
retrospective and prospective case registries, series of endoscopies and biopsies, as well as 
population-based studies (6). Despite varying methodologies, epidemiological studies from 
industrialized countries have consistently described an increasing prevalence and incidence of 
EoE over the past decades (23). 
 
1.3.1 Prevalence of EoE 
Prevalence estimates of EoE differ, depending on several factors, including study design,  
study population, and the case definition being used (22). Most prevalence estimates of EoE 
have been obtained through single-center studies with defined catchment areas (24-29). 
However, some studies have used national databases or population-based methods, aiming to 
generate prevalence estimates applicable to the general population (23, 30-32). Due to the 
chronic and non-fatal nature of EoE, studies tend to report increasing prevalence rates 
regardless of geographic location (22). EoE may present throughout the lifespan, from infancy 
to old age, although most patients present with the disease in third and fourth decades (33). 
  
Generally, studies report prevalence estimates of EoE ranging between 0.5-1 cases per 1000, 
translating to 50-100 cases per 100 000 persons. In the USA, most prevalence estimates vary 
between 30-90 cases per 100 000 persons (24, 28, 31, 34-38). The most extensive American 
epidemiological study was conducted by Dellon et al. in 2014, comprising more than  
35 million individuals (31). Health insurance claims were collected from a database 
representing the commercially insured population of the USA. Using a previously validated 
disease definition, an overall EoE prevalence of 56.7 per 100 000 persons was estimated (31). 
Furthermore, in 2016, Mansoor et al. (37) aimed to address the epidemiology of EoE in the 
US. Using an extensive commercial database of electronic health records,  
patients diagnosed with EoE and a history of PPI use between 2010 and 2015 were identified. 
An overall EoE prevalence of 25.9 per 100 000 persons was reported (37). 
 
The prevalence estimates obtained from the mentioned studies are consistent with estimates 
from other countries e.g. Australia (26), Canada (32), Switzerland (25) and  
Spain (27). However, some studies have reported prevalences that deviate from the normal 
range. For instance, a Danish study demonstrated a prevalence rate of 13.8 per 100 000, 
whereas a study from Northern Sweden estimated a prevalence rate of EoE at 400 per 100 000 
(30).  




Among the most recent epidemiological evidence on EoE is a systematic review by Arias et 
al. (39). This review summarizes a selection of population-based studies investigating the 
epidemiology of EoE in North America, Europe and Australia. Based on the included 
population-studies, the pooled EoE prevalence rate was calculated to be 22.7 per 100 000 
persons per year, adjusted to 28.1 when considering studies with a lower risk of bias (39). See 
Appendix 1 for an overview of prevalence estimates from population-based studies. 
 
1.3.2 Incidence of EoE 
Incidence rates of EoE vary widely, ranging from 2.07 in the Netherlands to 12.8 in Ohio, 
USA (4, 40). A recent meta-analysis estimated a pooled EoE incidence rate of 3.7 per 100 000 
persons per year in children and adults (39). See Appendix 2 for an overview of incidence 
estimates from population-based studies.  
 
When interpreting incidence data, it is essential to consider variations in study methodology 
and geographic location. Regardless of methodological differences, studies unanimously 
report increasing trends in EoE incidence (41). This rapid surge is likely related to the 
growing recognition of EoE and increasing use of endoscopy in clinical practice (2). 
However, studies have shown that the increase in EoE incidence outpaces the increase in rates 
of endoscopy with biopsy, indicating a true increase in EoE incidence (2). 
 
1.3.3 EoE risk factors 
Presently, the most well defined risk factors for EoE include sex, ethnicity as well as atopic 
disorders including asthma, rhinitis and atopic dermatitis (42). Additionally, IgE-mediated 
food allergies have been linked to EoE development (6).  
 
Studies have consistently reported a male predominance in EoE, with an estimated male-to-
female risk ratio of 3:1 (43). Male predominance is reported in epidemiologic studies from 
Europe, Canada, the US, and in some Asian EoE cohorts (6). One suggested mechanism for 
the gender discrepancy is male inheritance of a risk related single-nucleotide polymorphism 
(SNP) in the gene for thymic stromal lymphopoietin (TSLP) on chromosome regions Xp22.3 
and Yr11.3. A similar association has not been found in females (44).  
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While cohorts of EoE patients have been reported worldwide, studies have reported that 
Caucasian populations seem to be disproportionally affected by EoE compared to Asian and 
African-American populations (33). The prevalence of EoE in Caucasians has been found to 
be three-fold higher compared with other races (45). A recent population-based study among 
more than 7000 EoE patients in the USA, reported that approximately 90% of the included 
subjects were Caucasian, while only 5.6% were Asian and 6.1% were African-American (37). 
Comparison studies have shown that African-American subjects are more likely to present 
with a normal appearing esophagus at endoscopy than Caucasians. Therefore, the diagnosis of 
EoE may be missed if biopsies are not obtained. However, studies controlling for referral and 
population bias have demonstrated that among patients suffering from symptoms of 
esophageal dysfunction, Caucasians are at higher risk of presenting with EoE (5).  
  
Furthermore, EoE is strongly associated with atopic diseases. Compared to the general 
population, EoE patients exhibit significantly higher rates of bronchial asthma, atopic 
dermatitis and allergic rhinitis (46). However, it remains unclear whether atopy predisposes to 
EoE (6). In 50-60% of cases, a personal history of atopy is documented prior to diagnosis of 
EoE. A systematic review comprising 21 studies and a total of 53,542 EoE patients and 
54,759 controls found that most of the studies did not provide standardized definitions of 
atopy (46). Regardless of this limitation, overall allergic rhinitis, eczema and bronchial 
asthma were significantly more common among EoE patients compared to controls (46). It 
has further been estimated that between 15-43% of EoE patients concomitantly suffer from 
IgE-mediated food allergies. This indicates that presence of IgE-mediated food allergy may 
represent a predictive factor in the subsequent development of EoE. 
 
1.4 EoE Pathogenesis 
The pathogenesis of EoE is believed to be complex, with disease development being under the 
influence of genetic, immunological, as well as environmental factors (47). However, EoE 
pathogenesis remains under investigation, and the precise mechanism of disease is yet to be 
elucidated (33). 
 
1.4.1 Genetic factors 
Studies of family history and twin concordance, genome-wide association studies (GWAS) as 
well as the consistently reported male predominance, point toward the presence of a genetic 
component to EoE (48). The genetic predisposition involved in EoE has been explored using 
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different approaches, such as the association with Mendelian and non-Mendelian diseases, 
GWAS, and the search for a specific gene (49). 
 
A higher prevalence of EoE has been reported in patients with hypermobile connective tissue 
disorders (CTDs), such as Loeys-Dietz (LDS), Marfan and Ehler-Danlos syndromes (50). The 
co-existence of EoE with these diseases is termed EoE-CTD, and it has been estimated that 
EoE increases the risk for CTD eightfold (51). Notably, the underlying pathologies of both 
EoE and CTD involve abnormal TGF-ß signaling and excessive production of TGF-ß (51). 
For instance, LDS results from gain-of-function mutations in the TGF-ß receptors, while 
Marfan syndrome type II is caused by mutations in connective tissue proteins that bind to 
TGF- ß, e.g. fibrillin 1 (52). 
 
Moreover, a Mendelian disease that has been reported to frequently co-occur with EoE, is 
severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome (53). This rare 
syndrome stems from homozygous mutations in desmoglein 1 (DSG1), a key constituent of 
desmosomes. Desmosomes are structures that attach the cell surface to the keratin 
cytoskeleton in order to maintain gastrointestinal barrier function and epidermal integrity. 
Interestingly, it has been demonstrated that DSG1 is decreased in EoE and is associated with 
impaired barrier function (54). Current literature also suggests an association between EoE 
and other atopic Mendelian disorders, including autosomal dominant hyper-IgE syndrome as 
well as a syndrome involving elevated levels of mast cell tryptase in the blood (54). 
 
GWAS have led to the recognition of various genetic alterations in EoE patients, including the 
genes encoding TSLP and calpain-14 (49). TSLP, a cytokine produced by epithelial cells, is 
responsible for initiating a Th2 cell-mediated response in dendritic cells (44).  An SNP has 
also been identified in the TSLP receptor gene, located on the Y-chromosome, and may 
explain the high prevalence of EoE observed in males (33). Similarly, a genome-wide genetic 
association of EoE has been described at the CAPN14 gene encoding calpain-14, a member of 
the calpain large subunit family (55). Calpains are cytosolic cysteine proteases that participate 
in several biological processes, such as cleavage of pro-interleukin-33 and STAT6 which in 
turn regulate allergic responses (55). It has been found that the expression of CAPN14 mRNA 
in esophageal epithelium is increased in active EoE, when compared with inactive EoE and 
controls. Interleukin-13 gives rise to an epigenetic alteration of the CAPN14 promotor, 
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thereby upregulating CAPN mRNA in esophageal epithelial cells. However, the precise role 
of CAPN14 in EoE development requires further investigation (55). 
 
Furthermore, single candidate-gene identification studies have described potential factors 
associated with EoE (56). For instance, an SNP in the CCL26 gene encoding eotaxin-3 has 
been related to EoE (56). Eotaxin-3 plays an essential role in the chemotaxis of eosinophils, 
and it has been demonstrated that its expression is increased in esophageal epithelial cells of 
EoE patients (57). A SNP has also been identified in the FLG gene encoding filaggrin, a 
structural membrane protein implicated in epithelial cells-extracellular matrix interaction (51). 
 
In 2014, Alexander et al. (58) investigated the respective roles of genetic heritability and 
environmental factors in EoE pathogenesis. The overall risk of EoE for first-degree relatives 
was reported to be 1.8%, whereas the risk for a sex-matched relative was reported to be 2.3%. 
Higher recurrence risk ratios (RRR) were demonstrated in brothers (64-fold), fathers (43-fold) 
and men (51-fold) when compared with sisters, mothers and women, respectively (58). In the 
same study, analysis of the Twins cohort found common family environment to play a greater 
role (81%) than genetic inheritance (14.5%) in EoE susceptibility (58). 
 
1.4.2 Environmental factors 
Due to the increasing prevalence, attention has been drawn to the role of environmental 
factors in EoE development (48). Factors that have been associated with a higher risk of EoE 
include premature delivery, birth by cesarean section, early exposure to antibiotics, food 
allergy, lack of breastfeeding, and residing in an area of lower population density (59). This 
may indicate that altered immune system stimulation in the early years of life confers a 
predisposition to EoE (60). 
 
Additionally, it has been suggested that an altered microbiome as well as the absence of 
microbe exposure at an early age may promote EoE susceptibility, as is the case for other 
atopic diseases e.g. asthma and atopic dermatitis (61). In 2015, Harris et al. demonstrated that 
EoE patients seemed to have an increased esophageal bacterial load relative to healthy 
subjects. In particular, they found Haemophilus to be significantly increased in untreated EoE 
patients (62). Another study showed a reversed association between Helicobacter pylori and 
pediatric EoE, suggesting a putative link between EoE and microbiota alterations (63).  
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1.4.3 Immune system factors  
In EoE, the lamina propria and submucosa of the esophagus is characterized by extensive 
eosinophilic infiltration. Various cytokines are believed to participate in the maturation and 
migration process of eosinophils, e.g. IL-5, IL-13 and granulocyte-macrophage colony 
stimulating factor (64). These cytokines are generated by different cell types, including 
esophageal epithelial cells, in response to stimulation by the antigen-presenting cells (APCs) 
(65). Interestingly, esophageal biopsies from EoE patients have disclosed a pattern of dilated 
interepithelial spaces, changed epithelial barrier function and a decrease in adhesion 
molecules and proteins involved in maintaining epithelial barrier integrity (66, 67). 
 
Pertaining to the evidence that shows a desmoglein-1 dependent altered barrier function in 
EoE, it has been proposed that increased esophageal permeability may promote the passage of 
antigens (65). These antigens may then lead to the activation of APCs and natural killer T-
cells. If adequately stimulated, these cells can further initiate a Th2 response through the 
production of IL-4 and IL-13. It remains unclear whether the diminished barrier integrity 
represents a contributor or a consequence in the context of eosinophilic inflammation (49). 
 
1.4.4 Disease mechanism and tissue remodelling 
EoE is presently recognized as an allergy-mediated disorder, triggered by the ingestion of 
casual food allergens and/or aeroallergens (2). However, it is not a traditional Immunoglobin 
E (IgE)-mediated reaction, reflected by the lack of resolution in EoE patients receiving anti-
IgE therapies (68). Alternatively, the eosinophilic inflammation in EoE is believed to be 
caused by an enhanced Th2 type immunological reaction driven by TSLP produced by 
esophageal epithelial cells (69). TSLP is a principal cytokine, involved in the initiation and 
enhancement of the Th2 type immunological reaction and is largely produced by epithelial 
cells and basophils (70).   
 
Initially, allergens are ingested and exposed to the esophageal epithelium. This is followed by 
permeation to the subepithelium, leading to the activation of dendritic cells via TSLP 
induction (71). Activated dendritic cells strongly promote Th2 cell proliferation, resulting in 
an increased production of IL-5, IL-3, IL-15 and several other cytokines associated with 
eosinophilic inflammation (71). IL-5 differentiates and contributes to the recruitment of 
eosinophils residing in the intramedullary or intravascular space (72). Furthermore, IL-13 and 
IL-15 trigger epithelial cells to secrete eotaxin-3, a strong chemotactic factor for eosinophils 
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(56). Additionally, IL-13 decreases the gene expression of epidermal differentiation complex, 
leading to an impaired barrier function of the epithelium (57). In cooperation with mast cells, 
locally accumulated and activated eosinophils produce TGF-β1. This, along with the activity 
of fibroblasts and periostin, generates fibrotic changes in the esophageal wall, giving rise to 
smooth muscle dysfunction (71). 
 
1.5 Clinical presentation 
 
1.5.1 Symptoms in children and adults  
EoE may debut at any age with a varied range of symptoms. However, the clinical 
presentation considerably differs between pediatric and adult populations (40). Infants and 
toddlers commonly present with nonspecific features, such as feeding difficulties, vomiting, 
nausea, heartburn, abdominal pain and failure to thrive (48). Older children typically exhibit 
symptoms that are more closely related to the esophagus, e.g. heartburn, chest pain and early 
signs of dysphagia, including slow and picky eating habits (73). In adolescents and adults, 
symptoms are more specific to esophageal narrowing and mainly include dysphagia and food 
bolus impaction (48). In a few cases, food bolus impaction can persist to the extent that an 
endoscopic removal procedure is required. Esophageal perforation has been reported as a 
possible endoscopy-induced complication, although spontaneous transmural esophageal 
rupture (Boerhaave’s syndrome) may also occur as a primary manifestation of EoE (74).  
 
Despite the discrepancy in clinical presentation between children and adults, EoE focused 
research has recently highlighted that symptoms may overlap across age groups. For instance, 
data show that some adults also experience chest pain and heartburn as prominent symptoms, 
possibly indicating an inflammatory component. In the same manner, children can also 
present with dysphagia (75). Furthermore, a recent study has proposed that gender is a factor 
in the initial clinical presentation of EoE. (76). The collected data suggest that men suffer 
from dysphagia and food bolus impaction more frequently than women. Conversely, 
heartburn and chest pain seem to be more commonly experienced by women (76) 
 
1.5.2 Natural history 
EoE is a chronic condition that usually has its onset during childhood, although in some 
individuals it becomes clinically evident in adulthood when they start to complain of 
dysphagia (77). Generally, symptoms appear in a hierarchal and pyramidal pattern from 
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infancy to adulthood, and largely depend on patients’ ability to communicate (73). The 
difference in symptoms between pediatric and adult populations with EoE, seems to be related 
to the time dependent disease progression. In children, the esophagus is typically 
characterized by active eosinophilic inflammation, whereas subsequent fibrostenotic changes, 
stricture formation and motility disorders represent key complications in adult patients (2). 
Damage of the esophageal muscularis propria is also believed to participate in symptom 
generation, although subepithelial fibrosis or muscle dysfunction is challenging to detect 
using conventional endoscopic procedures. This partly explains the inconsistency between the 
severity of clinical symptoms and the extent of endoscopic abnormalities that are found in 
EoE (78). 
 
The severity of symptoms varies widely among EoE patients, ranging from no notable 
symptoms, sporadic dysphagia with certain solid foods, to repeated events of food impaction 
nearly daily (79). Patients who experience mild and rare swallowing difficulties, may not seek 
medical care, likely considering the symptoms as part of their normal state. Therefore, it is 
essential to address that underdiagnosis as well as delayed diagnosis of EoE remains a 
challenge (79). 
 
Upon inquiring, several patients report that they have developed coping mechanisms to 
facilitate eating, thus symptoms may be overlooked or underestimated (5). Accommodations 
that are frequently made by EoE patients include eating slowly, avoiding dry or textured 
foods, cutting foods into small pieces prior to consumption, lubricating foods with sauces, 
using liquids to dilute and wash down solid foods, as well as avoiding foods that are likely to 
trigger dysphagia and impaction events (80). 
 
1.5.3 Symptom scoring 
As is the case for several chronic diseases, it is essential to identify the frequency, persistency 
and intensity of symptoms. Various scoring systems have been developed to provide a 
comprehensive assessment of EoE symptoms (73). In addition to providing greater precision 
in evaluating symptoms, scoring systems also function as standardized tools that are useful to 
monitor EoE over time and evaluate treatment effects in clinical trials (73).   
 
Patient-reported outcome (PRO) instruments have newly been developed and validated for the 
use in adult patients, such as the Eosinophilic Esophagitis Activity Index (EEsAI) and 
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Dysphagia Symptom Questionnaire (DSQ) (81). This scoring system aims to assess 
symptoms, behavioral accommodations, as well as biologic activity of adult patients with EoE 
over a 7-day recall period. It is extensive, accounting for frequency, severity and duration of 
dysphagia. Other factors, such as food impaction events, time required to eat a regular meal, 
frequency of pain while eating, as well as the use of coping mechanisms are also documented 
by the EEsAI (81). However, a prospective, observational study found that EEsAI score alone 
cannot predict endoscopic or histologic remission accurately (82). 
 
1.6 Diagnosis and evaluation 
 
1.6.1 Diagnostic criteria  
Essentially, the diagnosis of EoE relies on the presence of clinical, endoscopic and 
histological features, following exclusion of other etiologies (83). Current diagnostic criteria 
for EoE include presence of symptoms related to esophageal dysfunction, at least one 
esophageal mucosal biopsy demonstrating ≥ 15 eos/HPF, and persistence of esophageal 
eosinophilia following a PPI-trial, with exclusion of other causes of eosinophilia (7). Despite 
being a pathological feature, esophageal eosinophilia may be caused by various conditions 
including GERD, EGID, Crohn’s disease, celiac disease, achalasia, hyper-eosinophilic 
disorders, drug hypersensitivity and CTDs (84). 
 
1.6.2 Differential diagnosis: GERD 
The initial consensus guidelines for the diagnosis of EoE particularly focused on the exclusion 
of GERD, as evidenced by a normal esophageal pH monitoring or unresponsiveness to high-
dose PPI therapy (85). Thus, EoE and GERD were suggested to be mutually exclusive 
disorders (86). However, the idea of establishing a clear distinction between the two entities 
was soon challenged, drawing attention to the complex interplay that may exist between EoE 
and GERD (87). It was proposed that esophageal eosinophilia may appear as a manifestation 
of GERD, resulting from repeated exposure of the esophageal lining to gastric acid. 
Furthermore, GERD can predispose to EoE development by increasing esophageal mucosal 
permeability, thereby facilitating translocation of causal allergens (86). Conversely, EoE may 
contribute to GERD development via production of substances that trigger reflux and 
decrease esophageal acid clearance. Lastly, considering the high prevalence of GERD in 
Western adult populations, it is likely for EoE and GERD to coexist independently (88). 
Hence, EoE is not excluded by concurrent GERD (87). 
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1.6.3 Differential diagnosis: PPI-REE  
The initial goal of using a PPI trial was to distinguish GERD from EoE. This was based on 
the assumption that PPIs only exert acid-suppressive and anti-secretory effects, making 
GERD the only disorder responsive to PPIs (85). However, evidence emerged regarding a 
new subset of patients who have clinical, endoscopic and histological features compatible 
with EoE and yet experience clinical and histological remission in response to PPI therapy. 
These patients were recognized to have PPI-responsive esophageal eosinophilia (PPI-REE) 
(89).  
 
In 2016, a meta-analysis comprising 33 studies showed that administration of PPIs in patients 
with an EoE phenotype achieves clinical and histological remission in 61% and 51% of 
patients, respectively (90). A number of studies have proposed theories regarding the 
mechanisms of PPI-REE. One theory suggests that PPIs decrease levels of key mediators such 
as eotaxin-3, IL-4, IL-5 and IL-13. It remains unclear whether PPI-REE represents a subtype 
of EoE or GERD, although recent data indicate that EoE and PPI-REE share a similar 
molecular basis. Current diagnostic guidelines recommend EoE unresponsive to PPIs to be 
discriminated from PPI-REE. Before performing a diagnostic esophago-gastro-duodenoscopy 
(EGD), patients should be subjected to an 8-12 week PPI trial consisting of 20-40 mg x2 per 
day of any available PPI (91). 
 
Diagnostic approach and monitoring of EoE depend on repeated EGD, as there are currently 
no symptom tools, biomarkers, or pathognomonic traits that can replace clinicopathological 
monitoring (43).  
 









High dose PPI 
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1.6.4 Endoscopic features 
The endoscopic presentation in EoE is often characteristic, although not pathognomonic. 
Several endoscopic findings have been reported, including linear furrows, concentric rings, 
white exudates, esophageal strictures and reduced vascularity in the esophageal mucosa (77). 
Endoscopy and subsequent biopsies remain the most critical diagnostic assessments for EoE, 
allowing the identification of gross abnormalities as well as esophageal eosinophilia (33).  
 
Linear furrows which appear in a longitudinal manner in the esophagus, are rather frequent 
and specific compared with other endoscopic features of EoE (92). Concentric rings exist 
along the horizontal axis of the esophagus, a feature that is termed ‘ringed esophagus’ or 
‘trachealization’ in severe cases (93). Concentric rings require careful evaluation as subtle or 
transient rings may be found in GERD patients as well as in normal subjects exhibiting a 
potent gag reflex during the endoscopic procedure (93). White exudates histologically identify 
as microabscesses with the aggregation of a few eosinophils, which considerably resemble 
esophageal candidiasis (2). Persistence of eosinophilic inflammation may progress to 
subepithelial fibrosis in the esophageal wall, resulting in a narrow-caliber esophagus or 
esophageal stricturing. Occasionally, esophageal rupture occurs during the passage of the 
endoscope, suggesting mucosal fragility. In contrast to GERD, the middle and upper 
esophagus is also prone to perforation. Extensive inflammation and edema results in 
decreased vascularity, which manifests as thickening and whitening of the esophageal 
mucosa, commonly present in GERD patients. In some adolescent and adult patients with 
EoE, multiple polypoid lesions resembling esophageal papilloma are also observed. 
 
The underlying mechanism of each endoscopic feature remains unclear, although important 
knowledge has been gained from studies investigating prevalence and age-dependent 
variations (94). There is a considerable difference between clinical and endoscopic features in 
children and adults, which may be explained by the inflammatory nature of pediatric EoE 
versus the progressive fibrosis that develops with increasing age (94). In 2012, Kim et al. 
performed a meta-analysis that mainly consisted of retrospective studies in adult populations 
with EoE (95). The following pooled prevalence estimates of endoscopic findings were 
reported: 48% linear furrows, 44% concentric rings, 27% white exudates, 21% esophageal 
strictures, 9% narrow-caliber esophagus and 41% reduced vascularity in the esophageal 
mucosa. At least one endoscopic finding was present in 93% of the subjects (95). 
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The mentioned meta-analysis also highlighted the differences in endoscopic abnormalities 
between pediatric and adult populations with EoE. Concentric rings, strictures and furrowing 
were found to be more common in adults, while children more frequently presented with 
narrow-caliber esophagus, white exudates and decreased vasculature (95). The effect of age 
on endoscopic findings is related to the natural course of inflammation and indicates that 
several phenotypes of EoE exist. Furthermore, it may partly explain the significant differences 
in symptoms experienced by children and adults (96). 
 
 
Figure 2: Prevalence estimates of endoscopic findings. Based on data from Kim et al. (2012) 
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1.6.5 Histological features 
A recent meta-analysis demonstrated that the esophageal mucosa may appear normal in 20% 
and 7% of EoE patients from retrospective and prospective analyses, respectively (95). Prasad 
et al. reported that the diagnose of EoE was entertained in 10% of all patients with dysphagia 
and an esophageal mucosa that appeared normal at endoscopy (97). Therefore, a 
macroscopically normal esophagus does not exclude EoE as a potential diagnosis, making it 
necessary to obtain esophageal biopsies. This is particularly important in patients with 
unexplained dysphagia or food impaction (2). 
 
The histological demonstration of eosinophilic infiltration remains crucial for the diagnosis of 
EoE. Being the only gastrointestinal organ devoid of eosinophils, an esophagus with even a 
few infiltrating eosinophils is considered to be pathogenic (2). The density of mucosal 
eosinophils increases gradually from stomach to cecum. However, eosinophilic infiltration of 
the esophagus is not specific for EoE (2). Other clinical entities that may cause esophageal 
eosinophilia include, but are not limited to, GERD, celiac disease, Crohn’s disease, drug 
hypersensitivity, scleroderma, EGE and vasculitis. In clinical practice, GERD is known as the 
most common etiology behind secondary esophageal eosinophilia (98). Previously conducted 
studies suggest that GERD can cause <10 eosinophils to emerge in the esophageal mucosa. In 
contrast, a cut-off value of >15 eos/HPF has been proposed as the histological definition of 
EoE (7).  
 
Histological traits that are relatively pathognomonic of EoE include superficial distribution of 
eosinophils in the esophageal epithelium, degranulation of eosinophils, lamina propria 
fibrosis, and eosinophilic microabscesses (99). On the other hand, basal cell hyperplasia, 
papilla elongation and dilated intercellular space are abnormalities commonly found in EoE as 
well as GERD (99).  
 
In EoE, eosinophils have been observed to distribute in a heterogenous manner. Previous 
studies have reported diagnostic sensitivity to increase from 40-50% when obtaining a single 
biopsy to almost 100% with five or more biopsies (100). Consensus guidelines recommend 
two to four mucosal biopsy specimens to be obtained from the proximal and distal esophagus 
(7). Since some EoE patients present with a normal appearing mucosa at endoscopy, the 
importance of random biopsies has been emphasized in consensus recommendations. 
However, in patients with endoscopic abnormalities, white exudates and linear furrows 
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represent areas of more intense eosinophilia (2). This indicates that the histological site as 
well as the number of biopsies taken influences the histological detection of EoE. 
 
1.7 Management of EoE 
The current therapeutic approach of EoE includes pharmacological, dietary and endoscopic 
therapy (101). Treatment largely depends on the severity of symptoms or endoscopic findings 
e.g. esophageal narrowing and stricturing. Due to difficulties in evaluating symptoms 
objectively and systematically, histological improvement is generally used as the primary 
outcome parameter in clinical trials (81). 
 
1.7.1 Corticosteroid therapy  
When PPI therapy is unable to induce symptomatic and histological remission, topical 
glucocorticoids represent first line therapy for EoE (2). Glucocorticoids exert their effects by 
targeting key mechanisms involved in EoE: they inhibit proinflammatory cytokines in the 
esophageal mucosa, thus reducing mucosal migration of eosinophils (48). 
 
In 1998, systemic corticosteroids were demonstrated to be effective therapy for active EoE in 
a pediatric population (102). Ten years later, a prospective, controlled trial reported oral 
systemic prednisolone and swallowed topical fluticasone to be equally effective in terms of 
achieving histologic and symptomatic remission (103). However, systemic reactions, e.g. 
hyperphagia, weight gain and/or cushingoid characteristics were demonstrated in 40% of 
patients receiving oral prednisolone. In contrast, esophageal candidiasis was the only noted 
side effect of topical fluticasone, affecting 15% of patients (103). 
 
Various randomized trials in children and adults support the efficacy of topical corticosteroids 
for histologic remission in EoE patients (104, 105). In 2016, Murali et al. conducted a 
systematic review and meta-analysis of 5 randomized, placebo-controlled trials investigating 
the efficacy of topical corticosteroids (104). In total, 89 children and 85 adults were included. 
Patients receiving topical corticosteroids showed significantly higher complete histologic 
remission than the placebo group (odds ratio 20.81 and 95% CI 7.03-61.63). However, topical 
corticosteroid therapy did not show a statistically significant effect on symptom improvement 
in EoE (104). 
 
In contrast to histologic remission, data on symptomatic resolution are uncertain. A range of 
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clinical trials have not been able to show a statistically significant benefit of topical 
corticosteroids compared to placebo. A recent meta-analysis by Chuang et al. was not able to 
describe a clear effect of topical corticosteroids on symptomatic resolution, when compared 
with placebo (106). The discrepancy between histologic and clinical outcomes may be 
explained by variability regarding inclusion criteria, definition of symptomatic response, 
administered agents, dosing regimens, and treatment duration (6).  
Although consensus guidelines recommend topical corticosteroids as first-line medical 
treatment for EoE, no formulations are currently approved by the Food and Drug 
Administration (FDA) (5). The most frequently used topical corticosteroids include nebulized 
fluticasone and oral viscous budesonide. Recommended dosage of fluticasone is 440 mcg 
twice daily and 880 mcg twice daily in children and adults, respectively. Alternatively, 
budesonide 2 mg twice daily in adults and 1 mg twice daily in children can be administered 
(98). One study found that oral viscous budesonide, when compared with nebulized 
fluticasone, covers a greater length of the esophagus, has significantly longer contact time 
with the esophageal mucosa and attains significantly higher histologic remission (64% vs. 
27%) (107). Hence, histologic remission seems to be directly associated with higher mucosal 
contact time and the importance of appropriate administration methods in EoE treatment was 
emphasized (107).    
 
Current evidence does not indicate that an 8 to 12-week course of topical corticosteroids is 
associated with adrenal axis suppression (84). Other known side-effects of corticosteroids e.g. 
local candidiasis, bone demineralization and growth retardation in children, appear to be 
uncommon since swallowed topical corticosteroids undergo first-pass metabolism (48). Being 
a chronic disease, symptoms and eosinophilic inflammation commonly relapse within few 
weeks after discontinuation of topical corticosteroids, making several patients dependent on 
long-term therapy (73). At present, only 1 long-term, placebo-controlled trial has investigated 
the effect of low-dose swallowed budesonide 0.25 mg x2 daily. Low-dose budesonide 
maintained histologic and clinical remission more effectively than placebo, although complete 
histologic remission was only maintained in 35.7% of EoE patients over a 1-year period 









Esophageal dilation is a treatment modality reserved for patients who present with esophageal 
strictures or narrowing, the most severe complication associated with EoE (2). Most patients 
undergoing dilation are adults, as esophageal remodeling is a result of progressive and chronic 
eosinophilic inflammation (79).  
 
Three main types of dilation procedures have been described, and include the simple bougie, 
the wire-guided bougie and through-the-scope (TTS) balloon dilation (109). In a retrospective 
study, Runge et al. reported that during a 12-year period, 164 of 509 EoE patients underwent 
dilation 486 times in total at their hospital. The bougie procedure was performed in 
approximately 20% of the cases, while TTS dilation was used in 80% of the cases. The TTS 
procedure was able to extend the esophageal lumen further than the bougie method, with no 
significant increase in complications (109). 
 
The dilation must be carried out gently to avoid chest pain and esophageal tears secondary to 
mucosal fragility. The most critical complication associated with dilation is esophageal 
perforation (2). Previously it was suggested that dilation-related complications occur 
frequently, whereas recent systematic reviews report perforation rates of less than 1%, 
deeming dilation a safe procedure with the ability to induce short-term alleviation of 
symptoms in many patients (110, 111). Predictors for dilation-related complications include 
young age, upper esophageal stricturing, repeated dilations, and unsuccessful passage of the 
endoscope through strictures (112). Most patients experience symptomatic relief after 
dilation, although its durability seems to be insufficient. An extensive cohort study reported 
that more than 50% of EoE patients with dilation, required repeated procedures, particularly 
during the first year (113). 
 
1.7.3 Dietary therapy 
Initially, dietary therapy was observed to be an effective treatment option in children, 
emphasizing the role of food-allergen sensitization in EoE pathogenesis. Present literature 
describes three main types of dietary-restriction therapies in children and adults with EoE: the 
elemental diet, the allergy testing-directed elimination diet and the empiric elimination diet.   
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The elemental diet 
The elemental diet is based on exclusive feeding with a hypo-allergenic formula. As food 
allergies are commonly a reaction to ingested protein, the elemental diet aims to substitute 
whole protein with amino acids (84). 
 
In 1995, Kelly et al. described the beneficial effects of an exclusive amino acid-based diet in 
pediatric EoE management. The study found that a 6-week trial of elemental formula 
significantly reduced esophageal eosinophilia and clinical symptoms, with 8 out of the 10 
included children exhibiting complete remission (19). Peterson et al. confirmed the efficacy of 
the elemental diet in an prospective trial in adults, producing histologic response in 72% of 
subjects (114). More recently, a study in 17 adults showed significant reduction in 
eosinophilic inflammation and clinical symptoms following 4 weeks of elemental diet therapy 
(115). In 2014, a meta-analysis reported the elemental diet to have a histologic remission rate 
of >90% in children and adults, combined (114). 
 
The elemental diet is particularly beneficial in children who present with various IgE-
mediated food allergies and feeding difficulties, as it ensures complete nutrition while 
symptoms are treated concurrently (116). Retrospective cohort studies and a meta-analysis 
have confirmed superiority of the elemental diet, when compared with empiric and allergy-
testing directed diets (114). However, the acceptance of the elemental diet remains low among 
adults due to the high cost, unpalatability, the potential need for a gastric feeding tube, and the 
social isolation that may be experienced (43). 
 
Allergy-testing directed elimination diet 
Given the challenges and lack of patient adherence associated with the elemental diet, other 
dietary approaches have been developed and tested (101). The allergy-testing directed 
elimination diet is based on removal of foods to which the patient is sensitized (33). However, 
current evidence suggests that skin prick testing (SPT), atopy patch testing (APT) and serum 
food antigen-specific IgE-testing are not reliable methods for identifying causal food triggers 
(2). The etiology is not fully clarified, but likely supports the involvement of a delayed type, 
non-IgE-mediated mechanism underlying EoE pathogenesis (117). 
 
In 2002, Spergel et al. used a combination of SPT and APT to identify specific food triggers 
in a series of EoE children from Philadelphia (118). The results obtained from the SPT and 
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APT were used to tailor an allergy testing directed elimination diet for each child. 
Histological and clinical remission was achieved in 49% of the treated patients. Later, the 
research group revised the results, and reported an overall efficacy of 53% (119). However, 
allergy skin testing exhibited varying sensitivities and specificities, with less than 10% 
accordance between positive results in SPTs and APTs (119). Furthermore, a retrospective 
study among 22 adult EoE patients subjected to allergy testing directed elimination diet, 
clinical improvement was seen in 68% of the patients, while endoscopic improvement with 
significant reduction in esophageal eosinophilia was seen in 53% of the patients (120).  
 
Although some studies have proposed that allergy testing is useful in tailoring diets devoid of 
specific food triggers, similar results have not been reproduced by controlled studies (114). In 
a prospective study among EoE patients, SPT was able to identify food triggers correctly in 
only one of 20 patients (121). Furthermore, a study by Gonsalves et al. described poor 
performance of the SPT, revealing a positive predictive value of 13% for the identification of 
food triggers implied in EoE (122). A recent meta-analysis reported an overall remission rate 
of 45.5% with wide heterogeneity (95% CI 35.4%-55.7%) for the allergy testing directed 
elimination diet (114). 
 
Empiric elimination diet 
Due to the many challenges related to the elemental diet and the variable efficacy of skin 
allergy testing to identify specific food triggers in EoE, the six-food elimination diet (SFED) 
was developed (84). The SFED is based on empiric elimination of the six most common food 
groups associated with food allergy: wheat, cow’s milk, egg, soy, peanuts/tree nuts, and 
fish/shellfish (101). The SFED approach consists of a six-week diet period, followed by 
esophageal biopsies and clinical monitoring as each food group is reintroduced sequentially to 
allow identification of trigger foods (101).  
 
The SFED was initially studied in 2006 by Kagalwalla et al. in children with EoE (123).  
Following a 6-week period, clinical and histologic remission (<10 eos/HPF) was reported in 
74% of children who underwent the SFED (123). Subsequently, a retrospective study in EoE 
children extended the SFED to include foods that exhibited positive results upon allergy 
testing, leading to histologic remission in 81% of the study population (124). Gonsalves et al. 
prospectively studied 50 adult EoE patients subjected to an SFED extended to comprise foods 
showing positive allergy test results (122). Complete histologic remission was achieved in 
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70% of the study subjects. Furthermore, Lucendo et al. investigated the efficacy of the SFED 
approach in Spanish EoE patients, reporting a histologic remission rate of 73% whereas 
significant symptom improvement was achieved in all responder patients (125). Notably, this 
study extended the SFED to include legumes, corn and rice, as these foods are commonly 
associated with food allergies in the study population (125). 
 
Recently, a meta-analysis summarized seven observational studies and reported that the SFED 
was able to induce histologic remission in EoE with an overall efficacy of 72%. Notably, a 
heterogeneity value of 0% was calculated, indicating high concordance of the remission rate 
(95% CI 66%-78%). Due to the homogeneity and greater adherence rates, consensus 
guidelines recommend empiric elimination diets for the initial dietary management of EoE 
(114).  
 
2 OBJECTIVES  
Not all EoE patients experience disease improvement with the use of corticosteroid therapy, 
and some experience symptom relapse upon completion of the corticosteroid course. Current 
evidence supports the use of the SFED as a treatment option for children and adults with EoE. 
However, the SFED has not been tested on the Norwegian population and their dietary habits. 
The goal of this project is to assess the effect of the SFED on esophageal histopathology and 
symptoms in adult patients with an established EoE diagnosis. This thesis aims to present the 
existing results of our study, with emphasis on the histopathological and symptomatic features 
of EoE. 
 
3 SUBJECTS AND METHODS 
 
3.1 Study population 
This prospective intervention study was planned during the spring of 2016 and is currently 
being conducted at Haukeland University Hospital (HUS) in Bergen, Norway in collaboration 
with the University of Bergen (UiB). Adult patients (18-60 years of age) with an established 
diagnosis of EoE, attending the Gastroenterology Outpatient Clinic at HUS were 
consecutively invited to participate in this study. Diagnostic criteria of EoE are consistent 
with current guidelines and primarily include i) symptoms of esophageal dysfunction  
ii) esophageal eosinophilia ≥15 eos/HPF iii) unresponsiveness to PPI-therapy  
iv) exclusion of other causes of esophageal eosinophilia. 





Included patients could or could not have been treated with corticosteroids previously, but 
experiencing symptom relapse was necessary for inclusion in the study. In case of negative 
biopsy results or absence of clinical symptoms, patients were excluded from the study. The 
presence of clinical symptoms was essential, as the second phase of the study was exclusively 
symptom-based. Patients with reflux esophagitis, as indicated by histologic response to PPI-
therapy or a highly abnormal pH-monitoring were also excluded from the study. Patients 
undergoing medical treatment for their EoE did not meet eligibility criteria and were therefore 
not informed about the study. 
 
EoE patients below the age of 18 were not included, as this study aims to assess the effect of 
an empiric SFED in the adult population. The rationale for not including patients above the 
age of 60 years was to ensure diet compliance to the best possible extent. Subjects below the 
age of 60 were considered more suited to follow the SFED, as it requires time, motivation as 
well as comprehensive understanding of the diet. 
 




Subjects between 18-60 years of age 
 
Subjects responsive to PPI-therapy  
Confirmed EoE diagnosis  
 
Clinical remission 
Presence of clinical symptoms Histologic remission  
 
No concurrent treatment Highly abnormal pH-monitoring 
 
 
3.2 Recruitment process 
All patients who met inclusion criteria and were interested in participating in the study, were 
contacted via telephone by one of the two gastroenterologists responsible for the study. 
During this phone call, the patient received information about the study protocol and was 
invited to give written consent (Appendix 3). This is an ongoing intervention study with 
continuous recruitment of patients meeting eligibility criteria. By April 2018, 15 patients had 
been included, out of which 11 had completed the SFED. 
                         
34 
 
3.3 Study design 
This intervention study aims to assess the efficacy of the SFED in the Norwegian population. 
The dietary treatment consists of two phases and includes elimination and reintroduction of 
the eliminated food groups. 
 
Baseline assessment  
In order to assess the effect of the SFED, a range of measurements and questionnaires were 
administered before and after the SFED. Corticosteroid formulations (systemic, swallowed, 
intranasal) were withdrawn at least six weeks prior to baseline procedures, and were 
prohibited throughout the course of the study. A six-week termination period was considered 
adequate for the corticosteroids not to interfere with any of the performed baseline 
measurements. Following this, all patients underwent PPI-therapy for two weeks as a means 
of excluding acid reflux as the cause of dysphagia. No restrictions were made on concurrent 
treatment with PPIs and antihistaminic drugs. 
 
At baseline, physical examinations, upper endoscopy with esophageal biopsies, blood tests, 
SPT, impedance manometry and ambulatory pH-monitoring were performed on each included 
patient. Additionally, esophageal symptoms were assessed structurally by the EEsAI 
(Appendix 4), whereas the 36-Item Short Form Survey (SF-36) (Appendix 5) was used for 
evaluation of functional health and well-being of patients. A questionnaire assessing each 
patient’s dietary habits over the past year was also completed (Appendix 6).  
 
Prior to starting dietary treatment, a master’s student in clinical nutrition provided each 
patient with a thorough introduction to the SFED. Height and weight measurements were also 
performed. Dietary consultation was tailored according to each patient’s lifestyle and 
consisted of a PowerPoint presentation of the SFED with several illustrations of diet-friendly 
foods. Along with the presentation, a comprehensive list of foods to eliminate along with 
substitute products, and a 2-week menu suggestion with recipes were handed out (Appendices 
7 and 8).  
 
Phase 1: Elimination  
After completion of baseline procedures, all patients were required to follow the SFED for a 
6-week period, avoiding consumption of wheat, milk, eggs, fish/shellfish, nuts/treenuts and 
soy. During the SFED-period, patients were offered reimbursable prescription for two 
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nutritional supplements: Fresenius Kabi ProvideXtra drink and Nutricia Elemental 028 Extra. 
Follow-up procedures were performed at the end of the SFED-period and included a new 
upper endoscopy with esophageal biopsies, blood tests and impedance manometry. A new 
assessment of esophageal symptoms (EEsAI) and well-being of patients (SF-36) was carried 
out. A new weight was also recorded for each patient.  
 
Phase 2: Reintroduction  
Evaluation of symptomatic response was carried out both through conversation with each 
patient and qualitative comparison of the EEsAI answered before and after dietary treatment. 
Symptomatic improvement was considered to be present if the response to the following 
validated question “In the past 7 days, how often have you had trouble swallowing?” had 
improved from baseline to the end of the SFED. In cases of symptomatic improvement, 
patients were subjected to sequential reintroduction of each food group eliminated in the 
SFED. Patients were requested to consume each reintroduced food daily for a 2-week period. 
If symptoms did not recur during a single-food challenge, the given food was considered to be 
well-tolerated. In case of symptomatic relapse, the given food was removed from the diet and 
a wash-out period was initiated before reintroduction of the next food group. The duration of 
the wash-out period varied from one patient to another.  
  
3.4 Study timeline  
 
Visit 1: During the first meeting, patients received thorough information about the study, and 
were requested to document their voluntary participation with a written consent form. 
Baseline endoscopy with esophageal biopsies, blood tests and SPT were performed, given that 
the patient had not undergone these tests rather recently. The obtained biopsies as well as 
blood samples were stored in a biobank at HUS. 
 
Visit 2: During the second meeting, an esophageal manometry and a 24-hour ambulatory pH 
monitoring was performed. The patient received the following written questionnaires:  
EEsAI x2, SF36 x2, and diet compliance questionnaires (Appendices 9 and 10), to be filled 
out during the course of the study. 
 
Visit 3: The third meeting consisted of a thorough consultation with a master’s student in 
clinical nutrition prior to starting the SFED. The patient received detailed information about 
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the foods to be eliminated and food products that could be used as substitutions. Written and 
oral information about the SFED was supplemented with a 2-week menu suggestion and a 
recipe booklet to facilitate the 6-week diet period. During this meeting, the patient was also 
asked to hand in the following completed questionnaires: EEsAI x1 and SF36 x1.  
 
SFED period: The next six weeks consisted of strictly following the SFED. After three 
weeks of following the SFED, the patient was asked to complete and hand in a 3-week diet 
compliance questionnaire. Questions and problems concerning the diet could be directed to 
the responsible physicians or master’s student in clinical nutrition via e-email or telephone. 
 
Visit 4: This meeting took place after the completion of the SFED, with the aim to evaluate 
the effect of the diet. Follow-up endoscopy with biopsies and blood tests were performed. The 
patient was requested to hand in the following completed questionnaires: EEsAI x1, SF36 x1 
and 6-week diet compliance questionnaire. 
 
Visit 5: A new manometry was performed during this meeting. If clinical remission had been 
achieved, the patient could enter the reintroduction phase of the study. Systematic 
reintroduction of food groups was not necessary if the patient did not experience clinical 
and/or histologic remission, as evidenced by post-SFED biopsy results.  
 
Reintroduction phase: Patients experiencing symptomatic and/or histologic improvement 
were referred to a new consultation with a master’s student in clinical nutrition prior to the 
reintroduction phase. Each eliminated food group was reintroduced separately at 14-day 
intervals. Following reintroduction of each food group, the patient was contacted via 
telephone and inquired about symptomatic relapse.  
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•Handouts:EEsAI x2 and SF36 x2 
Visit 3 
•SFED consultation
•Handouts: SFED booklet, recipes+sample menu 
•Hand in: EEsAI x1 and SF36 x1  
SFED-
period
•6 week SFED intervention
•Contact: telephone/e-mail
•Hand in: diet compliance (3 weeks)
Visit 4
•New endoscopy + biopsies
•New blood tests
•Hand in: EEsAI x1, SF36 x1 







Reintroduction of each 
food group separately. 
14 days per food.
Exclusion of suspected 
trigger foods
No Exclude from the study. Corticosteroid therapy.
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3.5 Design of the SFED  
As European Commission legislation concerning labelling of foodstuffs requires producers to 
label their products as gluten-containing rather than wheat-containing, we implemented a 
gluten-free diet rather than a wheat-free diet as a practical matter. While following the SFED, 
foods containing wheat starch and soy lecithin were considered safe to eat, as was the case for 
foods labelled with “traces of” allergens that cause slow reactions. The rationale for allowing 
foods containing traces of allergens was that the likelihood of an allergic reaction is minimal, 
as the amounts are generally very small. Recommended supplements during the elimination 
phase included calcium, vitamin D and omega-3 fatty acids in addition to a 
multivitamin/mineral supplement. If patients were unable to eat adequate amounts of food 
while following the SFED, they were encouraged to consume ProvideXtra drink or Elemental 




3.6.1 Upper endoscopy and esophageal biopsies 
Upper endoscopy with biopsy procedures were performed prior to and after six weeks on the 
SFED. All analyses of biopsy specimens were performed by an experienced board-certified 
pathologist at the Department of Pathology, Haukeland University Hospital. The effect of the 
SFED on histopathology was assessed by comparing results from the biopsies obtained before 
and after the SFED.  
 
Endoscopies were performed during conscious sedation using a flexible 9 mm caliber 
Olympus gastroscope. Biopsy specimens were obtained from the proximal, middle and distal 
part of the esophagus by a standard needle biopsy forceps. A total of 6-9 biopsy specimens 
were obtained from each patient and fixed in 10% formalin before histopathologic analysis 
was performed according to routine procedures. Sections from the formalin-fixed specimens 
were placed on microscope slides to be stained with eosin and hematoxylin. A pathologist 
examined the histologic stains using a light microscopy for the quantification of eosinophils in 
the most densely inflamed areas. Peak eosinophil count/HPF was determined after evaluation 
of the eosinophil count in 2 or 3 HPFs. 
 
In our study, histologic response was categorized into three groups; mild, moderate and severe 
eosinophilia. Mild eosinophilia was defined as a peak eosinophil count of <25 eos/HPF, 
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moderate eosinophilia was defined as 25-100 eos/HPF, while severe eosinophilia was defined 
as >100 eos/HPF.  
 
3.6.2 Blood tests 
Blood samples were drawn from each patient before starting and after completion of the 
SFED. These general blood tests included eosinophilic cell count and a celiac disease panel, 
consisting of various micronutrients indicative of nutritional status. At baseline, blood tests 
additionally included standard airway and food panels (RAST), total serum-IgE, and serum-
IgE against hazelnut and shrimp. The standard airway panel (Phadiatop) comprised dust 
mites, cat, horse, dog, moulds, birch, timothy grass and mugwort, while the standard food 
panel consisted of cow’s milk, egg white, cod, wheat, soy and peanut. All blood tests and 
analyses were performed at the Laboratory for Clinical Biochemistry at HUS.  
 
A total serum IgE concentration ≥120 kU/L is considered to be elevated, suggesting the 
presence of an allergic process. Specific serum-IgE concentrations ≥0.35 kU/L is considered 
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General blood tests Allergy specific blood tests  
B-Hemoglobin S-Immunoglobulin E (IgE) 
E-Mean corpuscular volume (MVC) S-D1 Dermatophagoides pteronyssinus 
B-Leukocytes  S-M2 Cladosporium herbarum 
B-Thrombocytes S-G6 Timothy grass 
S-Thyroid stimulating hormone (TSH) S-T3 Birch 
S-Cobalamin  S-W6 Mugwort 
S-Folate S-E1 Cat  
S-Ferritin S-E3 Horse  
S-C-reactive protein (CRP) S-E5 Dog 
S-Creatinine S-F1 Egg white 
S-Sodium (Na) S-F2 Cow’s milk  
S-Potassium (K)  S-F3 Cod  
S-Calcium (Ca) S-F4 Wheat 
S-ALAT  S-F13 Peanut 
S-ALP S-F14 Soy 
S-Vitamin D S-F17 Hazelnut 
S-Gamma-Glutamyl transferase (GGT) S-F24 Shrimp  
S-Albumin  
S-Parathyroid hormone (PTH)  
S-IgA    
S-IgG  
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3.6.3 Skin prick test 
The SPT method is based on the principle that allergens that are exposed to the epidermis in 
sensitized individuals will bind to IgE-antibodies that are attached to receptors on the surface 
of mast cells (126). The allergen creates cross-links between Ig-E antibodies, leading to 
activation and subsequent degranulation of mast cells. Upon degranulation, mast cells release 
several mediators including histamine, cytokines and chemokines, causing an acute local 
inflammatory reaction (127). 
 
Each patient underwent an SPT before the SFED period, with the purpose to identify IgE-
mediated allergies against specific foods. The results obtained from the SPT, combined with 
the immunological blood tests were used to direct the reintroduction phase and to prevent 
adverse reactions. Antihistamine medications e.g. Cetirizin, Aerius, Xyzal, Zyrtec and 
Phenamin were discontinued 72 hours prior to the SPT (126). The procedure was performed 
by an allergy specialized nurse at the Section for Clinical Allergology, Department of 
Occupational Medicine, Section of Allergy, HUS. Patients were tested with a standard panel 
of inhalant allergens and food allergens, in addition to shrimp and hazelnut.   
 
During the SPT, droplets of solution containing test allergens were applied on the inner 
forearm using a disposable lancet. Each solution droplet was separated from the next by  
1-2 cm to avoid false-positive reactions due to cross-contamination of test allergens (126). 
With the aid of a small plastic probe, the epidermis was gently pricked to allow the solution to 
enter just below the surface of the skin. Excess allergen solution was removed with a tissue, 
and during the next 15-20 minutes, the area of skin was observed for characteristic changes. 
Appearance of a wheal (raised, itchy bump) and flare confirmed that sensitization to a 
particular allergen was present (128). The size of the wheal was used as an indicator of the 
degree of sensitivity to the allergen, although medical history and clinical symptoms were 
taken into account when interpreting the clinical relevance of the SPT. (126). A mean wheal 
diameter of ≥ 3 mm was used as the cut-off value for positive SPT. A positive histamine 
control as well as a negative saline control test was also included. The purpose of the 
histamine control was to ensure that test allergens were applied appropriately and to exclude 
negative SPT results due to potential drug interactions. The negative control was used to 
exclude the presence of dermographism, a condition which complicates interpretation of the 
SPT (126). 
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3.6.4 High-resolution manometry  
HRM has replaced conventional manometry as the primary method for assessment of 
esophageal motor function (129). Displayed and interpreted by esophageal pressure 
topography (EPT), this method provides an in-depth evaluation of esophageal motility by 
allowing calculation of the amplitude of contractile events occurring in the esophagus and its 
sphincters (129). 
 
Patients underwent HRM at baseline, and a new HRM was also performed following 
completion of the SFED. The effect of the SFED on esophageal motility was assessed by 
comparing HRM data obtained before and after the SFED. The procedure was carried out 
after at least a 6-hour fasting period, using a high-resolution catheter with 36 solid-state 
circumferential sensors spaced at 1 cm intervals. Initially, the HRM catheter was calibrated by 
applying external pressure, and a topical anesthetic was applied to the patient's nasal cavity. 
The catheter was then positioned transnasally, stretching through the hypopharynx to the 
stomach. Adhesive tape was used to fix the HRM-catheter to the nose. Once the catheter had 
been inserted and fixed, resting sphincter pressure was assessed over a 20-30 second period of 
calm breathing without swallows. The patient was then asked to swallow 10 mL of water in  
5-10 turns. Data interpretation was performed according to the Chicago classification (CC), 
which is used to categorize motility disorders in a systematic manner, by applying objective 
measures of esophageal sphincter and peristalsis (129).  
 
The Chicago classification and EPT metrics 
A key characteristic of the CC is the classification of esophageal motor disorders into 
pathological conditions never present in normal subjects and conditions deviating from the 
norm yet not necessarily indicative of pathology. The CC mainly divides physiological 
dysfunction into the following: i) achalasia ii) esophagogastric junction (EGJ) outflow 
obstruction iii) major disorders of peristalsis iv) minor disorders of peristalsis (130). See 
Appendix 11 for a complete overview of The Chicago Classification version 3.0.  
 
A range of metrics have been developed for the quantification of esophageal function in EPT: 
Integrated relaxation pressure (IRP) measures the ability of the EGJ to relax upon 
swallowing. IRP represents a complex metric and is defined as the mean minimum EGJ 
pressure during four seconds of relaxation within 10 seconds of swallowing starting at upper 
esophageal sphincter (UES) relaxation (129). Normal IRP is defined by an upper of  
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15 mmHg, although reference values may vary depending on the manometric apparatus being 
used. Distal Latency (DL) is another EPT metric, defined as the interval between UES 
relaxation and contractile deceleration point (CDP), a concept describing the physiologic 
transition from esophageal peristalsis to emptying. On the basis of DL, contractions are 
defined as being premature or of normal latency (lower limit of normal: median DL 4.5 
seconds). Distal contractile integral (DCI) is a measure of the vigor of the distal esophageal 
contraction, taking into account contraction amplitude, duration as well as the length of the 
distal esophagus (129). The obtained DCI values are used for the classification of contraction 
vigor in the following groups (131): 
  
1) DCI >450 mmHg·s·cm and <8000 mmHg·s·cm is defined as normal 
2) DCI >100 mmHg·s·cm, and <450 mmHg·s·cm is defined as weak peristalsis  
3) DCI <100 mmHg·s·cm is defined as failed peristalsis  
4) DCI >8000 mmHg·s·cm is defined as hypercontractile  




3.7.1 Symptom scoring - EEsAI 
In our study, patients were considered to have symptomatic response to the SFED if the 
frequency of troubled swallowing decreased from baseline to follow-up, as assessed by the 
following validated EEsAI item: “In the past 7 days, how often have you had trouble 
swallowing?”. Additionally, symptomatic response was evaluated through conversation with 
each patient after completion of the elimination phase. If symptomatic improvement was 
present, the patient underwent sequential reintroduction of foods.   
 
All patients completed the EEsAI before the start of the SFED and at the end of the 6-week 
SFED period, with the aim to evaluate the effect of the SFED on esophageal symptoms. Prior 
to the development of the EEsAI, no other PRO instrument fulfilled all validation criteria 
recommended by the FDA (132). The EEsAI is specifically developed for the assessment of 
dysphagia severity in EoE patients. A total of 11 questions are asked in the EEsAI. Firstly, the 
EEsAI focuses on dysphagia induced when consuming eight different food consistencies that 
have been selected based on dietary consumption patterns in USA, Canada and Europe. 
Further, it inquires into dietary and behavioral adaptations for the same food consistencies, as 
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well as frequency, pain severity and duration of dysphagia. The obtained score serves as an 
indicator of dysphagia, while accounting for accommodating symptoms e.g. food avoidance, 
slow eating and careful chewing. The score is validated in 7-day recall period, selected after 
statistical evaluation and patient input (73). 
 
The EEsAI is based on information about EoE patients from Switzerland and the US, 
collected via surveys, focus groups and semi-structured interviews. The construct validation 
process of the EEsAI was performed using the Patients Global Assessment of Disease activity 
(81). However, a recent prospective multicenter study has described a modest correlation 
between distinct EEsAI cut-offs and endoscopic or histologic disease activity. Thus, it is 
important to assess EoE activity using a multimodal approach consisting of symptom 
reporting, as well as objective measures including endoscopic and histologic findings (82). 
 
Scoring system of the EEsAI 
The EEsAI international study group has developed a scoring system for the EEsAI. Severity 
of dysphagia (VDQ) as well as behavioral accommodations (AMS) are assessed by the 
EEsAI. Question number 1, 3 and 4 provide information, although they are not used for score 
calculation. Question number 2, known as the Visual Dysphagia Question (VDQ), assesses 
the degree of dysphagia experienced when consuming the following eight food consistencies: 
solid meats, soft foods, dry/sticky rice, ground meats, fresh white bread (untoasted), porridge, 
raw fiber-containing foods and French fries. Questions 5-8 evaluate behavioral adaptations for 
the same eight food consistencies by inquiring about food Avoidance, food Modification and 
Slow eating (AMS). 
 
Initially, questions 2, 5, 6, 7 and 8 are used to score the VDQ and AMS. A VDQ score of 0 
reflects very mild dysphagia, while a score of 10 reflects highly active dysphagia. In the same 
manner, an AMS score of 0 and 10 indicate mild and serious behavioral adaptation, 
respectively. Further, a total EEsAI PRO score can be obtained by scoring questions 9, 10 and 
11 in addition to the VDQ and AMS questions. 
 
VDQ scoring  
Each food consistency is given a score based on the degree of difficulty experienced during its 
consumption. If the patient does not experience any difficulty when eating a given food 
consistency, a score of 0 is given. Mild difficulty corresponds to a score of 1, while moderate 
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difficulty corresponds to a score of 2. In cases of severe difficulty, a score of 3 is given. 
Finally, all food consistency scores are summarized and divided by the number of relevant 








N1: the number of food consistencies graded with mild difficulties 
N2: the number of food consistencies graded with moderate difficulties 
N3: the number of food consistencies graded with severe difficulties 
D:  the number of relevant food consistencies  
 
AMS scoring  
For each of the eight food consistencies, four questions related to behavioral adaptation are 
scored. For a specific food consistency, no behavioral adaptation is scored as 0. Eating a food 
consistency slower than others corresponds to a score of 1 (N1), while modifying a food 
consistency corresponds to a score of 2 (N2). The presence of slow eating as well as 
modification of a food consistency is given a score of 3 (N3), and avoidance of a specific food 
consistency is given a score of 5 (N4). The AMS can be calculated by using the following 
formula, where D represents the number of relevant food consistencies. The AMS can be 








N1: the number of food consistencies with “Yes” to slow eating only 
N2: the number of food consistencies with ‘Yes’ to food modification only 
N3: the number of food consistencies with ‘Yes’ to both slow eating and modification 
N4: the number of food consistencies with ‘Yes’ to avoidance 
D:  the number of relevant food consistencies 
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Overall PRO scoring  
The calculated VDQ and AMS scores, as well as the answers to the remaining EEsAI 
questions can be used to obtain an overall PRO score, ranging between 0 and 100. The higher 
the PRO score, the more pronounced the symptoms are considered to be. This scoring system 
was provided by the international EEsAI study group in April 2017. 
 
3.7.2 SF-36 
In this study, the SF-36 was used to evaluate the effect of the SFED on health-related quality 
of life (HRQOL). Hence, all patients were requested to fill out the SF-36 before the start of 
the SFED, as well as at the end of the 6-week SFED period. The SF-36 is a generic 
questionnaire designed to quantitatively measure health status in the general population and in 
subjects suffering from medical conditions (133). 
 
The SF-36 is an abbreviated version of 149 validated health-related questions, originally 
described in a comprehensive medical outcomes study (134). Studies have reported high 
reliability and reproducibility of the SF-36 among patients presenting with similar health 
conditions (135). Validity of the SF-36 has also been established across differing health 
conditions, with consistent differences observed between subjects with medical conditions 
and the general population (136). Thus, the SF-36 is a valuable tool that can be used to 
monitor health status in specific and in general populations, to evaluate treatment effects, and 
to assess relative burden of diseases (137). 
 
The questionnaire consists of 36 items that can be divided into eight subscales for 
quantification: Physical Functioning (PF), Role limitations due to Physical health (RP), Role 
limitations due to Emotional functioning (RE), Energy/vitality (VT), Emotional Well-Being 
(EWB), Social Functioning (SF), Bodily Pain (BP) and General Health (GH). Further, these 
subscales can be compiled into two main components: a Physical Component Summary 
(PCS) and a Mental Component Summary (MCS) for a 4-week recall period (134). 
 
Each subscale is scored separately, providing an eight-scale score profile. Given that the 
patient has completed at least half of the SF-36 items within each subscale, scores are 
weighted and transformed into a scale from 0 (reflecting severe disability) to 100 (reflecting 
no disability) (134). The PCS and MCS scores are generated using specific algorithms, with 
each subscale contributing differently to these measures (138). 




In this study, score calculation was done according to the 36-Item Short Form Survey Scoring 
Instructions provided on https://www.rand.org/health/surveys_tools/mos/36-item-short-
form/scoring.html. 
 
• Step 1: Each of the 36 items are recoded on a scale from 0 to 100.  
 
• Step 2: The scored items belonging to a specific subscale are averaged together to provide a 
separate score for each subscale. The number of items that constitute a subscale varies. PF is 
made up of ten items, while EWB and GH consist of five items each. RP and VT consist of 
four items each, RE of three questions and both SF and BP consist of only two items each.  
 
• Step 3: The PCS and MCS scores are calculated by summarizing the four subscales that 
constitute each of these components, and then dividing this figure by the number of subscales 
that the PCS and MCS are made up of.  
 
𝑃𝐶𝑆 =









3.7.3 Dietary habits 
Before starting the SFED, patients were requested to complete a questionnaire that assesses 
dietary habits during the previous 12 months. Specifically, this self-administered 
questionnaire functioned as a checklist of the food groups that were eliminated during the 
SFED, with frequency response options for patients to report how often each item had been 
consumed over the past year. For each food group, frequency response options included 
“daily”, “weekly”, “monthly” and “never”. In cases where patients responded with “never” 
they were asked a follow-up question about why the given food had not been consumed. This 
follow-up question could be answered with “allergic”, “I dislike the given food” or “other 
reasons”. When responding with “other reasons”, patients were asked to elaborate. 
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3.7.4 Dietary compliance questionnaires   
After completing three weeks of the SFED, dietary adherence was assessed in all patients 
using a compliance form. Patients were requested to fill out the same compliance form at the 
end of the 6-week SFED period. The dietary compliance form included visual analogue scales 
(VAS) of general satisfaction with the diet, self-reported compliance and satisfaction with the 
diet as symptom management. Additionally, the compliance form consisted of questions with 
multiple answer options. These questions were related to deviations, inquiring how 
frequently, which foods and for what reason foods that were not included in the SFED had 
been consumed during the diet period. 
 
3.8 Data analysis 
A database was created in Microsoft Excel® based on biopsy results as well as scores 
obtained from the study questionnaires. GraphPad Prism version 7.04 for Windows, 
GraphPad Software (La Jolla California USA) was used for graphic representation and 
statistical analyses. Two or more different normality tests were applied to all values before 
performing statistical hypothesis testing.  
 
3.9 Ethical considerations 
The intervention was conducted in agreement with the ethical principles of the Declaration of 
Helsinki (DoH) and was approved by the Regional Committees for Medical and Health 
Research Ethics (REK Vest) in August 2016 (Reference number: 2016/1090). Informed, 
written consent was collected from all patients prior to the start of the study. Participation was 
entirely voluntary, and withdrawal from the study was possible at any time without further 
justification. 
 
All personal information was de-identified and handled in a confidential manner. The 
obtained blood samples and biopsies are stored in Biobank Haukeland and are reserved for 
use in this study only. Study patients had the right to both access and rectify their registered 
data on oral or written request. In case of withdrawal from the study, patients could demand 
deletion of all test samples and personal information, unless this material had already been 








Among the recruited subjects, only one dropped out of the study. Additionally, two patients 
were excluded as esophageal biopsies at baseline showed no eosinophilic cells, while one 
patient was excluded due to lack of symptoms at baseline. Currently, a total of 11 patients 
have completed the SFED. Out of the patients who completed the SFED, one was later 
removed from the dataset, as it was discovered that baseline biopsies did not show 
eosinophilic infiltration. This patient was therefore removed from the dataset and was not 
included in data analyses, despite having completed the entire study course. 
 
4.1 Demographics  
Baseline demographics for the total study population, showed a male predominance and a 
mean age of 29 years at inclusion in the study. Further, all included subjects were of 
Caucasian ethnicity and presented with dysphagia, while food impaction was present in more 
than half of the study subjects.  
 
Table 3: Demographics and clinical characteristics for the study population at baseline 
 
 
Characteristic  Patients completing the SFED (n=10) 
 
Mean age (years) ± SD  
 
28.7 ± 5.64 
 
Mean weight (kg) ± SD 84.8 ± 9.40 
 
Mean BMI (kg/m2) ± SD  
 
26.7 ± 2.97 
Sex (n) 
      Male 










Presenting symptom (n) 
      Dysphagia 





Self-reported allergies (n) 
     Dietary allergens 
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The questionnaire that was used to assess dietary habits during the past 12 months, showed 
that 9 out of 10 patients had avoided consumption of at least one of the foods that were 
inquired about. The reasons for avoiding one or more foods varied between patients, although 
allergy was most commonly reported as the reason for food avoidance.  
 












Patient no. Foods avoided Reported reason for avoidance 
1 Shellfish Allergy 
2 Nuts  Allergy 




4 Egg + Shellfish 
Peanuts + Nuts 
Dislike  
Allergy 
5 Nuts Allergy 
6 Shellfish Allergy 




8 Milk + Dairy products + Egg 
Fish + Shellfish + Peanuts + Nuts  
Allergy 
Allergy 




10 None None 
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4.2 Blood test results and SPT results 
Allergy blood tests taken at baseline included total s-IgE, as well as specific s-IgE against egg 
white, cow’s milk, cod, wheat, peanut, soy, hazelnut and shrimp. Standard airway panel 
testing (Phadiatop) was performed on all patients and was found to be positive in 9 out of 10 
patients. 
 
• Reference value of total s-IgE for adults: <120 kU/L.  
• Reference value of specific s-IgE for adults: ˂0.35 kU/L.  
 
Elevated levels of total s-IgE were found in 6 out of 10 patients. Values of specific s-IgE 
ranged from undetectable food allergen-specific IgE in serum to more than 100 kU/L, 
reflecting very high levels of food allergen-specific IgE 
 
 Table 5: Allergy blood test results for each individual patient at baseline 
For specific s-IgE, negative test values (˂0.35 kU/L) are denoted by ‘Neg’. Positive test values (≥0.35 kU/L) are 

























1 137 Neg Neg Neg Neg Neg Neg Neg 4,6 
2 39 Neg Neg Neg Neg Neg Neg Neg Neg 
3 411 0.54 Neg Neg 0.43 Neg Neg 0.71 Neg 
4 377 0.74 Neg Neg 1.4 4.84 0.75 52.1 Neg 
5 257 Neg Neg Neg Neg Neg Neg 9.53 0.85 
6 94 Neg Neg Neg Neg Neg Neg Neg 6.78 
7 155 1.56 Neg Neg 2.49 0.63 Neg 1.34 Neg 
8 2690 5.87 13.1 43.7 5.37 >100 19.2 67.5 8.33 
9 24 Neg 0.37 Neg Neg Neg Neg Neg Nm* 
10 54 Neg Neg Neg Neg Neg Neg Neg Neg 
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SPTs were performed on all patients prior to starting the SFED. In cases where patients had 
undergone an SPT rather recently, existing test results were used as it was deemed 
unnecessary to perform the procedure again. In patient no. 2 and 6, SPT results could not be 
interpreted due to the presence of dermographism and absence of reactivity to the positive 
histamine control, respectively.  
 
• A wheal diameter <3 mm is considered a negative SPT reaction. 
• A wheal diameter ≥3 mm is considered a positive SPT reaction 
 
Among the eight dietary allergens employed, peanut was the most common food found to 
trigger a response by SPT. Cod, wheat and hazelnut triggered a response in two patients each, 
while egg white, cow’s milk and shrimp triggered a response in one patient each. Soy 
produced negative test results in all patients. Positive SPT reactions showed wheal diameters 
ranging from 3 mm to 9 mm.  
 
Table 6: SPT results for each individual patient, obtained at baseline 
Negative SPT results (<3 mm) are denoted by ‘Neg’. Positive SPT results (≥3 mm) are specified with measured 
wheal diameter in mm. * Dermographism. ** Not testable as positive histamine control showed no reactivity.  
N.A = not available. 
Patient   Eggwhite  Cow’s milk  Cod  Wheat  Peanut  Soy  Shrimp Hazelnut 
1  N.A N.A N.A N.A N.A N.A N.A N.A 
2*  Pos Pos Pos Pos Pos Pos Pos Pos 
3  Neg Neg Neg Neg Neg Neg 3 mm 3 mm 
4  Neg Neg Neg Neg 3.33 mm Neg Neg Neg 
5  Neg Neg 4.5 mm Neg 4 mm Neg Neg 4 mm 
6**  Neg Neg Neg Neg Neg Neg Neg Neg 
7  Neg Neg Neg 4.5 mm Neg Neg Nm* Nm 
8  4.5 mm 4.5 mm 4.5 mm 4.5 mm 9 mm Neg Neg Neg 
9  Neg Neg Neg Neg Neg Neg Neg Neg 
10  Neg Neg Neg Neg Neg Neg Neg Neg 
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4.3 Clinical response: EEsAI 
Symptomatic improvement was evaluated via individual dialogue with each patient and 
comparison of answers before (baseline) and after the SFED (six weeks) to the following 
validated EEsAI question (Item 9): “In the past 7 days, how often have you had trouble 
swallowing?”. An improvement in response from baseline to six weeks was required for 
patients to start the reintroduction phase. 
 
In 7 out of 10 patients, symptomatic improvement was evident when assessed through 
conversation and change from baseline to six weeks. Patients no. 2, 5 and 10 reported to have 
negligible or no symptomatic improvement, as was reflected by their unchanged responses to 
EEsAI item 9 from baseline to six weeks.  
 
Table 7: Symptomatic response of the SFED assessed through change in EEsAI item no. 9 
Patient no. Baseline response to item 9 Follow-up (six weeks) response to item 9  
1 1-3 times  0 times  
2 >3 times  >3 times 
3 >3 times 1-3 times 
4 1-3 times 0 times 
5 Daily  Daily 
6 1-3 times 0 times 
7 1-3 times 0 times 
8 4-6 times 1-3 times 
9 Daily 0 times 
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P-value: 0.0156  
Table 8: Scoring for EEsAI Item 9 regarding frequency of dysphagia, adapted from the EEsAI 
scoring manual 
Question Short name Options Score 
How often have you 
had trouble 
swallowing? 
 Frequency of TS Never 
1-3 times / week 







A Wilcoxon matched pairs signed rank test was conducted to compare frequency of troubled 
swallowing at baseline and six weeks. Before the SFED intervention, our cohort of patients 
had a median score of 27 (IQR=15), whereas a median score of 7.5 (IQR=24) was found at 













































Figure 6: Change in median Item 9 score from baseline to six weeks. Interquartile range is 
indicated by whiskers.   
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P-value: 0.1261  
As stated previously, the effect of the SFED on esophageal symptoms was not exclusively 
assessed through dialogue and qualitative comparison of troubled swallowing frequency at 
baseline and six weeks. In addition, the EEsAI was scored to provide additional information 
about severity of dysphagia and degree of behavioral adaptation in our patients. 
 
VDQ is a measure of dysphagia severity and is scored on a scale from 0 (no symptoms) to 10 
(most severe symptoms). A paired-samples t-test was conducted to compare VDQ scores 
before (baseline) and after the SFED-intervention (six weeks). The obtained p-value 
demonstrates that there was no statistically significant change in dysphagia severity from 




























Figure 7: Change in VDQ scores (severity of dysphagia) for each individual from baseline to 









AMS is a measure of behavioral adaptation by EoE patients and is scored on a scale ranging 
from 0 (no behavioral adaptation) to 10 (most behavioral adaptation). 
 
A paired-samples t-test was conducted to compare AMS scores before (baseline) and after the 
SFED-intervention (six weeks). The obtained p-value shows that there was no statistically 































Figure 8: Change in AMS scores (behavioral adaptation) for each individual from baseline to 











The total PRO score considers both the VDQ score and AMS score, in addition to three 
EEsAI items related to frequency, duration and pain perception of troubled swallowing. The 
PRO is scored on a scale from 0 (no symptoms) to 100 (most severe symptoms). 
 
A paired-samples t-test was conducted to compare total PRO scores at baseline and after the 
SFED-intervention. The obtained p-value shows that there was no statistically significant 
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4.4 Quality of life: SF-36 
The PCS (summary of physical QOL) is scored on a scale ranging from 0 (low HRQOL) to 
100 (high HRQOL). The graph below shows that our patient cohort exhibited rather high  
MCS and PCS scores compared with mean summary scores in the general Norwegian 










































Figure 10: Mean PCS and MCS scores at baseline, by age-groups: 20-29 years and 30-39 
years. Dashed lines show mean PCS and MCS scores derived from a general population 
















A paired-samples t-test was conducted to compare PCS scores at baseline and after the SFED-
intervention for the total study population. The obtained p-value shows that there was not a 
statistically significant change/improvement in physical health-related QOL from baseline 











































The MCS (summary of mental health-related QOL) is scored on a scale ranging from 0 (low 
HRQOL) to 100 (high HRQOL). 
 
A paired-samples t-test was conducted to compare MCS scores at baseline and six weeks. The 
obtained p-value shows that there was not a statistically significant change/improvement in 
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The PCS and MCS are comprised of four subscales each. The difference from baseline to six 
weeks varies, being negative for some and positive for some subscales. A more marked score 
difference from baseline to after the SFED intervention can be seen in GH and SF than the 
other subscales. Differences in each subscale score before and after the SFED have not been 






































































































Figure 13: Mean change in each of the eight subscale scores from baseline to end of SFED-













4.5 Relationship EEsAI and SF-36 
It is logical to assume that an overall improvement in symptoms, as shown by a decreased 
PRO score from the EEsAI is followed by an improvement in HRQOL, as shown by 
increased MCS and PCS scores. Theoretically, the change in PRO variable should therefore 
be inversely correlated with the change in MCS and PCS variables. 
 
A Pearson product-moment correlation coefficient was computed to assess the relationship 
between the change in symptoms (PRO) and the change in physical quality of life (PCS) from 
baseline to end of the SFED-intervention. There was a negative correlation between the two 
variables (r= -0.11), although this correlation was not statistically significant (p= 0.7623). The 
R2 for this correlation analysis is 0.01209, meaning that only 1.21% of the variation in PCS 
score change can be explained by variation in PRO score change.   
 





C o rre la t io n  b e tw e e n  c h a n g e  in  P R O  a n d  P C S  s c o re s 
P C S  C h a n g e




Figure 14: Scatter plot showing the relationship between change in overall PRO score 
(symptoms) and the change in PCS score (physical quality of life) from baseline to end of the 
SFED-intervention) for each individual. The inverse correlation is not statistically significant. 
 
 




A Spearman rank correlation coefficient was computed to assess the relationship between the 
change in symptoms (PRO score) and the change in mental health-related quality of life (PCS 
score) from baseline to end of the SFED-intervention. There was a positive correlation 
between the two variables (r= 0.5879), however this correlation was not statistically 
significant (p= 0.0806). 
 
 




C o rre la t io n  b e tw e e n  c h a n g e  in  P R O  a n d  M C S  s c o re s
P R O  c h a n g e




Figure 15: Scatter plot showing the relationship between change in overall PRO score 
(symptoms) and the change in MCS score (mental health-related quality of life) from 













4.6 Histologic response 
A Wilcoxon matched pairs signed rank test was carried out to compare eosinophil counts in 
the esophagus at baseline and after the SFED-intervention. Before the SFED intervention, our 
cohort of patients had a median peak eosinophil count of 80 eos/HPF (IQR=50). After the 
SFED intervention, peak eosinophil density significantly decreased to 10.5 eos/HPF 
(IQR=35.75). Hence, the SFED intervention was successful with regard to inducing histologic 
































Figure 16: Change in peak eosinophil count/HPF for each individual from baseline to six 
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After the 6-week SFED treatment period, no histologic change was seen in patients no. 2 and 
5, with peak eosinophil counts found to be similar at baseline as well as at six weeks. 
However, the remaining eight patients in our cohort showed decreased peak eosinophil 
densities. Among the eight patients who experienced histologic improvement, complete 
histologic remission was seen in three patients. The other five patients exhibited between 56-
98% reduction of their esophageal eosinophilia.  
 
Table 9: Change in peak eosinophil density from baseline to six weeks for each individual 
patient, also expressed as percentage eosinophilia reduction.  






1 30 0 100% 
2 50 50 0% 
3 100 2 98% 
4 524 0 100% 
5 100 100 0% 
6 25 11 56% 
7 60 0 100% 
8 200 40 80% 
9 100 25 75% 
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At baseline, no patients presented with mild eosinophilia, eight patients presented with 
moderate eosinophilia while two patients were categorized as having severe eosinophilia. 
After the 6-week SFED intervention, six patients had mild eosinophilia, four patients had 
moderate eosinophilia, while no patient had severe eosinophilia.   
 
Table 10: Overview of number of patients (n) within in each category of eosinophil density 
before the SFED intervention and after the SFED intervention. 
Peak eosinophil count category    Baseline (n) Six weeks (n) 
<25 eos/HPF (mild)    0 6 
25-100 eos/HPF (moderate)    8 4 
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4.7 Manometric findings 
 
















LESP=Lower Esophageal Sphincter Pressure. IRP= Integrated Relaxation Pressure. DCI=Distal Contraction Integral. IC=Ineffective Contractions. ABD=Abnormal Drainage 
                           Baseline Six weeks 
Patient  LESP  IRP Mean DCI % IC ABD      LESP IRP Mean DCI % IC ABD 
1  2.6 -3.8 531  
5/10 failed 





2 16.5 5.6 684 
1/10 failed 
45% 64%    5.0 5.5 1846    
1/10 failed 
0% 0% 
3 1.2 -0.1 650  
1/8 failed 
36% 18%    7.2 1.9 704  
1/4 failed 
73% 45% 
4 5.9 1.2 364  
4/5 failed 





6 12.8 6.3 739  
3/10 failed 





7 26.9 2.1 1581    
1/10 failed 
10% 50%    7.7 3.1 1257  
2/9 failed 
22%  11% 
9 20.0 18.6 253 
6/10 failed 
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HRM results show abnormally low resting pressures of the LES in three patients. Upon 
swallowing, all patients exhibited normal nadir pressures (IRP) except patient 9. Peristaltic 
function varied much with one (patient 4) showing almost only failed contractions (very low 
pressures), while others had borderline normal contractions. Patient 7 exhibited normal 
peristaltic function, with only one failed peristaltic wave. Abnormal drainage of saline was 
seen in all patients upon swallowing. Drainage was also the only parameter that improved 
clearly in most patients from baseline to the end of the elimination diet.  
 
4.8 Self-reported compliance 
 
Self-reported compliance at 3 weeks 
A self-administered questionnaire was used to evaluate compliance throughout the 
intervention phase. When asked if they had followed the SFED during the past three weeks, 
eight patients responded with “yes” and two patients responded with “partly”. The following 
table shows the response results of the items that included a VAS-scale (0-100 mm). A high-
degree of self-reported adherence was reported by the study patients, with a mean of 95.50% 
at week 3. 
 
Table 12: Self-reported compliance at week 3 of the SFED. Data are presented as mean ± SD. 
 
How challenging was it to follow 
the SFED (0-100, where 100 is 
very challenging) 
How carefully have you followed 
the SFED the past 3 weeks?  
(0-100, where 100 is full 
adherence) 
How satisfied are you with the 
SFED for symptom relief? (0-100, 
where 100 is very challenging) 
 
37.70 ± 19.14 
 
 
95.50 ± 8.24 
 
61.40 ± 35.13  
 
 
The patients were requested to provide a reason for dissatisfaction with the SFED, if this was 
the case: one patient reported no dissatisfaction with the diet, three patients reported 
dissatisfaction due to lack of symptomatic effect, two patients responded that they missed 
foods that were not included in the SFED, whereas one patient reported the extra economic 
cost as the reason for dissatisfaction. Three patients reported more than one reason for 
dissatisfaction with the SFED: one patient responded with “time consumption” “missing 
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restricted foods” and “extra economic cost”, one patient responded with “missing restricted 
foods” and “extra economic cost”, while the last patient responded with “missing restricted 
foods” and “boring in terms of taste and variation”.  
 
Further, the patients were inquired about deviations from the diet: six patients reported 
“none”, three patients reported “1-2 deviations during the three weeks” and one patient 
reported “1-2 per week”. Among the four patients who had deviated from the diet, one 
reported consumption of milk and soy, one reported consumption of wheat and nuts, one 
reported consumption of milk only, while the last patient reported wheat only as their 
deviating food. Only one of the four patients had consumed a prohibited food on purpose, 
while the three others had unintentionally consumed foods not included in the SFED. 
 
In response to how satisfied they were with the dietary guidance given prior to the start of the 
SFED, seven patients responded with “very satisfied”, one patient responded with “satisfied” 
and two patients responded with “OK”.  
 
Self-reported compliance at 6 weeks 
When asked if they had followed the SFED during the past six weeks, eight patients 
responded with “yes” and two patients responded with “partly”. The following table shows 
the response results of the items that included a VAS-scale (0-100 mm). In similarity with the 
3-week compliance evaluation, a high-degree of self-reported adherence was also reported at 
the end of the SFED intervention with a mean of 95.30% at week 6.   
 
 
Table 13: Self-reported compliance at week 6 of the SFED. Data are presented as mean ± SD. 
How challenging was it to follow 
the SFED (0-100, where 100 is 
very challenging) 
How carefully have you followed 
the SFED the past 3 weeks?  
(0-100, where 100 is full 
adherence) 
How satisfied are you with the 
SFED for symptom relief? (0-100, 
where 100 is very challenging) 
 
41.80 ± 28.69 
 
 
95.30 ± 5.68 
 
63.90 ± 35.51 
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Regarding dissatisfaction with the diet, four patients responded with “not dissatisfied”, 
whereas three patients were dissatisfied due to lack of symptomatic improvement. Two 
patients reported dissatisfaction as they missed restricted foods and also found the SFED 
boring in terms of taste and variation. One patient responded with only “boring in terms of 
taste and variation”. 
 
At this point, no dietary deviation was reported by five of the patients, while the other five 
patients reported deviations “1-5 times during the six weeks”. Among the five patients who 
had deviated from the diet, two reported consumption of soy only, one reported consumption 
of wheat only, one reported consumption of milk and egg, while the last subject reported 
consumption of multiple prohibited foods including soy, wheat, milk and nuts. Among these 
five patients, prohibited foods had been consumed unintentionally by all except one patient 
who justified his dietary deviation with “craving a food that was not included in the SFED”. 
 
In response to how satisfied they were with the dietary guidance during the course of the 
study, seven patients responded with “very satisfied”, while three patients responded with 
“satisfied”.  
 
4.9 Reintroduction findings  
At present, a total of 10 patients have completed the SFED intervention. Three of the patients 
did not experience symptomatic improvement by following the SFED, and therefore did not 
go through the reintroduction phase. Among the remaining seven patients, two are currently 
going through the reintroduction phase at different stages. Out of the five patients who have 
completed the reintroduction phase, four patients experienced symptomatic relapse upon 
reintroduction of wheat. One patient reported symptomatic relapse upon reintroduction of egg. 
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Figure 17: Preliminary results of the reintroduction phase presented as number of patients 









Patient Trigger food 
1 Wheat/Gluten 
2 No reintroduction 
3 Wheat/Gluten  
4 Egg 
5 No reintroduction  
6 Wheat/Gluten 
7 Wheat/Gluten  
8 Reintroduction ongoing 
9 Reintroduction ongoing 
10 No reintroduction 





5.1 Main findings 
We performed a prospective clinical trial, with the aim to evaluate the effect of SFED on 
esophageal symptoms and histopathology in adult patients with EoE. Furthermore, the effect 
of SFED on esophageal motility and HRQOL was assessed. All included patients followed 
the SFED for a minimum of six weeks. 
 
The SFED showed a high degree of effectiveness when evaluating symptomatic response via 
change in troubled swallowing. A statistically significant reduction in EEsAI Item 9 score 
from median 27 (IQR 15) at baseline to median 7.5 (IQR 24) at six weeks was found. In total, 
7 out of 10 patients reported improvement of dysphagia after the SFED-intervention and were 
motivated to start the reintroduction phase. There was no statistically significant reduction in 
dysphagia severity alone, as measured by the VDQ score. Similarly, no statistically significant 
change was observed in behavioral adaptation alone, measured by the AMS score. The 
composite PRO score derived from a combination of the VDQ, AMS and general dysphagia 
items, was reduced from mean 44.90 at baseline to 30.70 at six weeks although this reduction 
was not statistically significant (p=0.0667).  
 
With regard to histopathology, our study showed a high degree of effectiveness of the SFED. 
In our cohort of 10 patients, eight patients achieved more than a 50% reduction in their peak 
eosinophil counts. No difference in peak eosinophil count was found in two patients, while 
the median peak eosinophil count was significantly reduced from baseline (80 eos/HPF) to six 
weeks (10.5 eos/HPF) in our patient cohort (p=0.0078).  
 
Esophageal peristalsis, as evaluated by HRM did not change notably from baseline to six 
weeks, although an improvement was seen in drainage of saline. Our study did not find a 
statistically significant change in HRQOL, as assessed by the SF-36 questionnaire. A slight 
increase in physical QOL (PCS) and a slight decrease in mental health-related QOL (MCS) 
was seen from baseline to six weeks, although these changes were not statistically significant. 
Each of the eight subscales were not significance tested separately, as we deemed the 
relevance of single-subscale improvement to be limited in clinical settings.  
 
                         
73 
 
Among the seven patients who experienced symptomatic response to the SFED, five patients 
have completed sequential reintroduction of eliminated foods. At present, the reintroduction 
phase has been able to identify a causative dietary trigger in all five of these patients. A single 
trigger food was identified by all five patients, with the most common trigger food being 
wheat. Reintroduction of causative foods resulted in symptom recurrence for these patients, 
while the remaining two patients are currently undergoing the reintroduction phase. 
 
5.2 Discussion of findings 
Symptomatic response and EoE symptom scoring    
In our study, 7 out of 10 patients verbally expressed to be satisfied with the diet for symptom 
relief during follow-up consultations. In these seven patients, the response to the EEsAI item 
“In the past 7 days, how often have you had trouble swallowing?” accordingly improved from 
baseline to after the SFED intervention. Hence, these patients met the criteria for symptomatic 
improvement, and were subjected to subsequent reintroduction of the eliminated foods. This 
finding is consistent with previously conducted studies that have reported empiric elimination 
diets to effectively induce symptom improvement in EoE patients (120, 122, 125). 
 
It is important to address that the scores obtained from the EEsAI did not reflect significant 
symptomatic improvement. We found that dysphagia severity for specific food consistencies 
(VDQ) and behavioral adaptation (AMS) did not change significantly after the SFED 
intervention when considered separately. Similarly, no significant improvement was noted in 
the overall PRO score which collectively considers the VDQ, AMS and general dysphagia 
items. Since the PRO score represents the objective measure of symptom activity derived 
from the EEsAI, it is reasonable to state that the SFED was not able to significantly change 
the degree of symptom scoring in our group of patients. Intuitively, this may seem to be in 
direct contrast to findings from existing studies that have reported symptomatic response rates 
of similar magnitude for the SFED and topical corticosteroids; the proportion of patients with 
symptom improvement has been found to be 97% in children (123) and 94% in adults (122). 
Additionally, a recent meta-regression found the proportion of patients with symptom 
improvement to be 87.3% for SFED in children and adults combined, indicating that food 
allergens play a causative role in EoE (140).  
 
In light of the available evidence it would be reasonable to expect the SFED to cause an 
improvement in mean EEsAI scores to a greater extent than was seen among our patients. 
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However, comparability of our study with other clinical studies of the SFED is limited due to 
methodological differences. Firstly, none of the studies included in the meta-regression by 
Cotton et al. (140) used the EEsAI questionnaire for symptom assessment. Two of the studies 
in adult patients used a score validated for achalasia (125, 141), whereas one study used the 
Dysphagia Symptom Questionnaire (122). Among the remaining studies, one used the ELSA 
index consisting of a non-validated VAS for each of the most frequent EoE symptoms (142), 
while one used dichotomous patient-reported subjective improvement [yes/no] (120). The 
EEsAI is a comprehensive measure, inquiring into more aspects than only the presence and 
severity of dysphagia. Besides the VDQ and the items related to frequency and duration of 
dysphagia, the AMS also constitutes an important part of the EEsAI. The PRO score derived 
from the EEsAI thus represents a broader symptom description and is also sensitive to the 
presence/absence of behavioral adaptation. An improvement in dysphagia and food impaction 
alone does therefore not necessarily lead to an improvement in the overall PRO score. 
Moreover, the EEsAI uses a recall period of seven days for all the included items. The clinical 
presentation of EoE may vary, with some patients experiencing a relapsing and remitting 
course of symptoms. In such cases, the EEsAI may be unable to detect degree of dysphagia 
and behavioral adaptation, particularly if the patient upon completion of the questionnaire has 
been symptom-free for the past seven days. Perhaps, using dichotomous patient-reported 
symptom improvement or an instrument exclusively focused on esophageal dysfunction in our 
study, would yield results even more similar to those found in previously conducted studies. 
 
Additionally, the lack of effect of SFED on EEsAI scores may be attributed to the small 
sample size. Comparability of our study results with results from previously conducted studies 
is limited, as the number of patients in our cohort is substantially lower. The low sample size 
may have decreased the power of the study, which includes its ability to detect a potential 
effect and to prevent Type II errors. Furthermore, a small sample size increases the margin of 
error, leading to a subsequent decrease in the confidence level of the study (143). In contrast 
to a large sample size, a small sample size makes it difficult to detect an effect despite its 
presence in the population (144). Statistical significance is dependent upon both effect size 
and sample size. P-values are affected by sample size, as they provide information about 
whether an effect exists, but do not reveal the magnitude of the effect. In our patient cohort, 
mean PRO score changed from 44.90 at baseline to 30.70 post-SFED, translating to an effect 
size of 14.20. This shows that a decrease in overall symptoms was evident in our patients, 
although the p-value of 0.0667 did not reflect the effect to be significant.  
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One may also question whether a SFED period of six weeks was sufficient with regard to 
inducing behavioral changes. For instance, patients who have previously experienced food 
impactions upon consumption of tough food consistencies will probably require a longer 
duration of exposure training to feel confident about reintroducing such foods in their diets. 
The six-week SFED period was perhaps sufficient for inducing changes in esophageal 
symptoms, while other factors remained unchanged. Hence, the EEsAI may be more suitable 
in the diagnostic phase rather than in the initial evaluation phase of EoE treatment effect. By 
looking at only one element in the questionnaire, we did find a significant improvement from 
baseline to six weeks (Item 9). Lastly, dietary consultations revealed that many patients were 
not aware of the extent of their own symptoms prior to the SFED. Due to this lack of 
awareness, there is a possibility that the EEsAI scores obtained at baseline were affected by 
underreporting of symptoms.  
 
Histologic effect of the SFED 
With regard to treatment of histopathology, our study showed a high degree of effectiveness 
of the SFED. In our study, we found that 8 out of 10 patients achieved more than a 50% 
reduction in their pre-SFED eosinophil counts. The reduction in median peak eosinophil count 
from 80 eos/HPF at baseline to 10.5 eos/HPF after six weeks in our patient cohort was further 
found to be statistically significant (p=0.0078). Among the eight histologic responders, six 
achieved the histologic response threshold of <25 eos/HPF while two patients achieved the 
histologic response threshold of 25-100 eos/HPF following the SFED.   
 
This finding is in line with existing literature; Kagalwalla et al. found a 74% histologic 
response in a pediatric cohort (123). Similarly, Gonsalves et al. showed a 70% histologic 
response of the SFED in their adult cohort, using a treatment protocol similar to that in our 
study. It was also reported that 78% of patients had > 50% reduction in their peak eosinophil 
density (122). Recently, a mean histologic response rate of 69% was found for the SFED in a 
recent meta-regression analysis, with a corresponding decrease of 44.6 in eosinophil counts 
from baseline to six weeks (140). The histologic response found in our cohort was comparable 
and strengthens the idea of food allergens having a causative role in the majority of adult EoE 
patients. 
Notably, no reduction in eosinophil count was evident in two of our study patients. This 
finding may suggest reactivity to potential aeroallergens as well as dietary allergens not 
included in the SFED, cross-contamination, low dietary compliance, or the absence of allergy. 
                         
76 
 
As aeroallergens were not treated concurrently in our study, this may explain the histologic 
non-responders to some extent. 
 
A high eosinophil density, as well as absence of complications at baseline seemed to increase 
the possibility of histologic response to the SFED. This may indicate that patients presenting 
with an inflammatory rather than fibrotic phenotype, are more inclined to respond to dietary 
treatment. Studies assessing the effect of the SFED on EoE histopathology have defined 
histologic response in various different ways; as an eosinophil count threshold, as a percentual 
difference, or as a ratio (140). In our study, three thresholds of peak eosinophil counts were 
used to categorize histologic response, although previous clinical studies have commonly 
used lower eosinophil counts of ≤ 5 eos/HPF and ≤ 10 eos/HPF to define histologic response. 
The rationale for this mainly lies in the rather small sample size of our study. We also 
considered it equally important to emphasize the percentage decrease in peak eosinophil count 
in each patient, as the patients who did not reach threshold levels of mild eosinophilia still 
showed a substantial decrease in peak eosinophil counts from baseline to post-SFED. Some of 
the patients also reported to be satisfied with the SFED for symptom improvement and were 
thus willing to enter the reintroduction phase of the study.  
 
Despite the demonstrated effectiveness of the SFED in children and adults, it has currently not 
been able to attain histologic remission to the same extent as the elemental diet. In prior 
studies, the elemental diet has been able to achieve complete histologic remission (0 eos/HPF) 
in a greater proportion of patients (19). Esophageal biopsies in only two of our patients 
showed 0 eos/HPF after the SFED, while the remaining patients exhibited higher levels of 
eosinophil density. However, the restrictions placed on patients following the elemental diet 
may be compensated by the advantages of the SFED with regard to cost, palatability, social 
functioning and administration method. 
 
Manometric effect of the SFED  
Dysphagia and food impaction, the most common EoE symptoms in adults, are primarily 
believed to result from changes in the esophageal structure, e.g. concentric rings, furrows and 
strictures (145). However, dysphagia may also be experienced by patients without significant 
endoscopic findings. Hence, it has been proposed that esophageal dysmotility may also be 
involved in the pathogenesis of dysphagia (145). 
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A few studies have investigated the esophageal motor function in EoE patients with the aid of 
HRM. A case-control study using HRM found pan-esophageal pressurization to be the most 
common esophageal motor abnormality in EoE (48%), while peristaltic dysfunction was 
found in 28% of the included EoE patients. A more recent case-control study by van Rhijn et 
al. concluded that EoE disease duration is a risk factor for the development of abnormal 
esophageal motility, with reduced and failed peristalsis being more frequently present in EoE 
than in healthy controls (146). However, a manometric pattern characteristic for EoE has not 
been identified, hence the use of HRM is not deemed necessary for the diagnosis of EoE.  
 
To our knowledge, no other studies have evaluated the effects of the SFED on esophageal 
motility in EoE patients. In the patients who underwent HRM in our study, peristaltic function 
did not seem to change from baseline to six weeks, although notable changes were evident in 
saline drainage. Previously, it has been found that EoE patients commonly present with a 
thicker esophageal wall than normal subjects, partly due to an edematous mucosa. Hence, the 
improvement of saline drainage seen from baseline to six weeks, may be explained by a 
reduction of the esophageal wall thickness which occurred secondary to the endoscopic and 
histologic effects of the SFED. A thinner esophageal wall, leading to an increased lumen 
diameter, may have facilitated the passage of saline despite the absence of peristaltic function 
improvement (J. Hatlebakk, unpublished data). The need for further research on manometric 
assessment of EoE patients undergoing dietary therapy is clear.   
 
Impact of SFED on HRQOL 
In our patient cohort, the SFED was not able to produce a significant change in neither 
physical (PCS) nor mental health-related QOL (MCS). This was somewhat expected, as the 
patients included in our study already exhibited rather high PCS and MCS scores prior to the 
SFED-intervention. 
 
Recently, a study presented revised normative data to aid interpretation of SF-36 scores in 
Norwegian populations (139). Mean SF-36 subscale and summary scores for the general 
population were calculated by gender and age groups, estimating a mean PCS score of 53.57 
and a mean MCS score of 50.85 for the age category 20-29 years. In the age category 30-39 
years, a mean PCS score of 52.50 and mean MCS score of 51.52 was estimated (139). 
In our patient cohort, we found a collective mean PCS score of 82.72 and mean MCS score of 
78.10 at baseline. Considering that our patients were between 21-38 years of age, they 
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presented relatively high HRQOL compared with normative data for their age categories 
already at baseline. Hence, expecting a dramatic surge in HRQOL following the SFED-
intervention would be rather unrealistic in this cohort. 
 
Previously conducted studies using generic QOL instruments in adult EoE patients have 
reported inconsistent results. One study found no significant differences in HRQOL in EoE 
patients compared with control subjects (147). Another study by van Rhijn et al. did not find 
significantly different levels of PCS and MCS scores in EoE patients compared to a reference 
population, although VT and GH subscales were demonstrated to be significantly lower in 
young adult EoE patients (148). Additionally, a study reported EoE to have an impact on 
various domains related to mental health function, e.g. embarrassment, frustration and fear 
about disease outcomes, while physical health was described to be significantly better than 
that in patients with other chronic conditions. It is reasonable to assume that baseline SF-36 
results in our study are in line with existing research, as our patient cohort did not show 
decreased levels of HRQOL compared to a Norwegian reference population. We did not focus 
on each subscale separately, as we deemed the value of such data to be limited in clinical 
settings. However, during conversations with patients, more concerns were raised regarding 
social function than physical function, indicating that some SF-36 subscales are likely to be 
more sensitive to EoE than others.  
 
Further, in our study SF-36 summary scores did not significantly change despite symptomatic 
improvement being evident in 7 out of 10 patients when evaluated through the following 
EEsAI item: “In the past 7 days, how often have you had trouble swallowing?”. This finding 
coincides with existing literature in showing that treatment and subsequent symptomatic 
improvement does not necessitate improvements in HRQOL: previous studies using generic 
questionnaires have reported conflicting results on the effect of therapy on EoE patients’ 
HRQOL. In one study of Swedish adult patients receiving swallowed topical steroids, SF-36 
scores did not change despite the presence of dysphagia improvement (149). In another study, 
a moderate increase in PCS and MCS scores was found in adult EoE patients following the 
four-food elimination diet, although this change was insignificant (147). Similarly, dietary or 
pharmacological therapy did not significantly improve overall mean QOL, when assessed  
with the EoE-specific questionnaire EoE-QOL-A (150).  
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The inability of the SFED to affect HRQOL in our study may be attributed to our choice of 
instrument for HRQOL assessment. Firstly, one may question the ability of the generic SF-36 
to capture EoE-specific challenges. Symptoms are primarily limited to the esophagus, 
suggesting that EoE patients’ HRQOL can only moderately be explained by their health 
condition, especially when measured with a generic instrument. During dietary consultation, 
several social and emotional concerns related to EoE were verbally expressed by patients. The 
challenges addressed by patients were mostly linked to dietary avoidance and other meal-
related situations. The generic SF-36 does not sufficiently inquire about such sentiments, 
indicating that EoE-specific QOL instruments may be more appropriate to use in this category 
of patients.  
 
While an insignificant increase was seen in mean PCS from baseline to six weeks, an 
insignificant decrease was seen in mean MCS. Among mental component subscales, the most 
prominent change from baseline to post-SFED was seen in social functioning. During the six-
week SFED intervention, patients were encouraged to avoid eating at restaurants and to 
prepare meals to bring to work and social gatherings in order to minimize the chances of 
cross-contamination. Perhaps, the SFED may have been experienced as particularly limiting 
in social settings, consequently affecting social well-being to a greater extent than physical 
aspects of QOL.  
 
Reintroduction phase - The role of SPT and allergy blood testing 
The marked reduction of esophageal eosinophilia that we found in our patients, as well as the 
identification of causative triggers in all five patients who completed the reintroduction 
course, provide support to the idea that the EoE disease response is highly driven by food 
allergens. Among these five patients, wheat was found to be the most common trigger food. 
Similar observations have been made in other studies that have found milk and wheat to be 
the most frequently identified trigger foods in pediatric (123) as well as adult cohorts (122). 
Furthermore, all five patients experienced symptomatic relapse within three days of 
reintroducing the given trigger food. Notably, none of the five patients reported food allergies 
and/or intolerance to the detected trigger foods at baseline.  
 
One may argue that our preliminary reintroduction findings are consistent with other studies 
that have identified milk and wheat as common trigger foods, along with a rather quick 
recurrence of symptoms upon reintroduction of trigger foods (122). However, it is essential to 
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highlight the methodological differences between our study and previously conducted studies 
of the SFED with a resembling study design. For instance, the reintroduction phase in our 
study was merely based on patients’ self-experience of symptoms. After completing two 
weeks of reintroduction for a given food, patients were contacted by a master’s student in 
clinical nutrition and inquired about symptom recurrence. In contrast, other studies of the 
SFED have used upper endoscopies with biopsies following reintroduction of each/some food 
groups to determine the presence of disease recurrence (120, 122, 125). Repeated upper 
endoscopies with biopsies provide an objective measure of disease recurrence, whereas self-
experience of symptoms represents a subjective measure of disease activity with a greater 
degree of built-in uncertainty. A study by Safroneeva et al. demonstrated that symptoms only 
with modest accuracy reflect endoscopic or histologic remission. Hence, lack of symptoms 
alone may not be used to make inferences about lack of biologic disease activity (82). 
Perhaps, using self-reporting of symptoms in addition to upper endoscopies with biopsies 
after reintroduction of all foods or foods that led to symptom recurrence only, would be a 
more reliable method for identifying trigger foods. On the other hand, this would be an 
invasive protocol requiring patients to be even more flexible and motivated, which in turn 
may have impeded the recruitment process.  
 
Allergy blood testing and SPTs were performed on all included subjects, although their roles 
in EoE management remain uncertain. The degree of accordance between dietary triggers 
identified via food reintroduction and SPT results or s-IgE levels was demonstrated to be low 
by Lucendo et al. in a study of the SFED (125). In our study, 4 out of the 5 patients who 
detected a trigger food during the reintroduction phase were found to have negative SPTs to 
their identified trigger foods. Only one patient who reported symptom recurrence upon 
reintroduction of wheat, also exhibited a positive SPT to wheat. Three of the patients showed 
elevated levels of s-IgE against their identified trigger food, however these patients had 
elevated s-IgE levels against two or more other food allergens as well. Despite the low 
number of participants in our study, this finding may indicate that the use of SPT and allergy 
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5.3 Methodological considerations 
 
5.3.1 Dietary consultations 
We conducted an uncontrolled clinical trial, which represent a potential source of selection 
bias in our study, as all included subjects were motivated and willing to go through the SFED. 
Dietary education was not provided by the same master’s student in clinical nutrition during 
the first and latter half of the study. Although SFED education was provided individually 
throughout the study, we did not share a completely standardized format for the sessions. 
More comprehensive dietary education might have been given to some patients due to the 
experience that was gained along the study. Additionally, there may have been differences in 
how accessible the two master’s students were via telephone and e-mail throughout the course 
of the study. As the study progressed, increased availability of allergen-free food products 
along with improved allergen labelling possibly facilitated the SFED period. The mentioned 
factors may have affected dietary adherence, which may in turn have had implications for 
how well patients responded to the SFED both histologically and clinically.  
 
5.3.2 Questionnaire scoring methods 
The SF-36 and EEsAI completed at baseline and six weeks were scored by a single person 
according to official manuals. The obtained scores were not controlled by another person, 
which may have increased the likelihood of calculation errors being present in our database. 
The presence of such errors may affect results of statistical analyses, which consequently may 
lead to erroneous study conclusions. As the SF-36 scores and EEsAI scores represented 
important parameters of interest in our study, administering a more thorough protocol for 
questionnaire scoring could have been appropriate. The low sample size in our study further 
increases the importance of precise calculations, as potential errors have a greater impact on 
statistical test results than in larger sample sizes.  
 
5.3.3 Data collection 
Due to logistical limitations, weight and height measurements could not be performed on all 
patients at baseline and/or at six weeks. For some patients, self-reported weight and/or height 
was recorded in our database. Although we did not aim to assess the effect of the SFED on 
body-weight in our study, previous studies have highlighted the importance of monitoring 
changes in weight and dietary habits in patients undergoing dietary management for EoE.   
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Performing weight and height measurements systematically would have yielded more 
accurate BMI estimates, that perhaps could have been used to propose an idea on how the 
SFED influenced this parameter in our study patients as well.  
 
5.3.4 Duration of the SFED and compliance assessment 
Based on previous prospective trials, we chose a six-week duration for the SFED phase. 
However, due to logistical aspects, follow-up measurements could not be performed during 
week seven for all patients. Thus, some patients were required to follow the SFED for a 
longer time period than six weeks. This in turn limits comparability within our patient cohort, 
and between our study and other studies with resembling study designs.  
 
In our study, we assessed adherence three weeks into the SFED, as well as upon completion 
of the SFED. Some patients did report unintentional/intentional deviations, which may have 
affected their histological and clinical response to the SFED. Perhaps, it would be more 
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6 FUTURE ASPECTS AND CONCLUSION 
Being a chronic disorder, it is essential to focus on the ability of therapeutic options for EoE 
to maintain disease remission. In some patients, multiple food allergens may be implicated, 
making it difficult to maintain a diet free of trigger foods in the long run. Although empiric 
elimination diets have demonstrated a high degree of effectiveness in inducing disease 
improvement, few studies have assessed long-term adherence and effects of empiric 
elimination diets, warranting further research on this subject.   
 
We prospectively examined the value of an empiric SFED followed by sequential 
reintroduction of food allergens. We found that the six-week SFED phase effectively 
improved symptomatic and histopathologic features of EoE in a cohort of Norwegian adult 
patients. These findings provide support to the role of food allergens in EoE pathogenesis in 
adults with EoE. Systematic reintroduction has demonstrated the ability to detect dietary 
triggers of EoE, corroborating results from previous studies in children as well as adults. As 
allergy blood testing and SPT did not effectively predict dietary triggers, the SFED followed 
by sequential reintroduction represents the preferred method for doing so. In conclusion, an 
empiric SFED with subsequent reintroduction of food allergens remains an effective  
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Author  Location Study Population  Time span  Estimated 
Prevalence  
(per 100 000) 






Adult + Pediatric  1976 – 2005  55.0 
Gill et al. (28) Huntington, 
West Virginia  
 
Pediatric 1995 – 2004  73.0 
Kim S et al. (38) 
 
South California Adult + Pediatric 2008 – 2013 45.0 
 
Spergel et al. (35) USA  Adult + Pediatric 2010  52.2 
 




Adult + Pediatric 2009 – 2011  
 
56.7 
Maradey et al. (36) 
 
USA Adult + Pediatric 2011 – 2014  50.6  
Mansoor et al. (37) USA Adult + Pediatric 
 
2010 – 2015  25.9  
Cherian et al. (26) Perth, Australia  Pediatric  1995, 1999, 2004 89.0  
 
Syed et al. (32) Calgary, Canada Adult + Pediatric 2004 – 2008 33.7 
 
Hruz et al. (25) Olten County, 
Switzerland 
 
Adult  1989 – 2004  
1989 – 2009 
23.0  
42.8  
Arias et al. (27) Castilla, Spain  
 




Dellon et al. (151) 
 
Denmark Adult  1997 – 2012 13.8  
Van Rhijn et al. (23)    The Netherlands Adult + Pediatric 1996 – 2010  4.1 
 
Ma et al. (152) Shanghai, China Adult 2015 400  
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Appendix 2: Incidence estimates of EoE in population-based studies 
 
Author Location Study 
Population 
Time Span Estimated 
incidence  
(per 100 000) 
Prasad et al. (34) Olmstead 
County, 
Minnesota 
Adult + Pediatric 2001 – 2005  9.5  
Noel et al. (40) Hamilton 
County, Ohio 
Pediatric 2003 12.8 
Syed et al. (32) Calgary, Canada Adult + Pediatric 2004 – 2008 11 
Giriens et al. (153) Canton of Vaud, 
Switzerland 
Adult + Pediatric  2004 – 2013  
 
0.16 – 6.3  
Dellon et al. (151) Denmark Adult + Pediatric  1997 – 2012  0.13 – 2.6 
Warners et al. (4) The Netherlands Adult + Pediatric  1996 – 2016 0.01 – 2.07 
Arias et al. (27) Castilla-La 
Manch, 
Spain  
Adult + Pediatric 2005 – 2011  6.4  
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Appendix 3: Written consent form and study protocol 
 
Forespørsel om deltakelse i forskningsprosjektet: 
Effekt av en eliminasjonsdiett ved eosinofil øsofagitt. 
 
 
Bakgrunn og hensikt 
Mange pasienter med eosinofil øsofagitt opplever liten eller ingen bedring av sykdommen ved 
behandling med prednisolon. Andre får tilbakefall av symptomer etter endt behandling med 
prednisolon, og/eller de får bivirkninger ved langvarig bruk. Eosinofil øsofagitt er en form for 
allergi, forårsaket av komponenter i mat eller luft. Derfor spør vi deg om du vil delta i en 
studie hvor vi vil forsøke diettbehandling som et behandlingsalternativ for eosinofil øsofagitt.  
 
Vi bruker en diett som på engelsk heter «Six Food Elimination Diet». Dette er en diett hvor 
seks vanlige matvarer/matvaregrupper blir utelatt fra kosten i seks uker. De seks 
matvaregruppene er melk, egg, hvete/gluten, fisk/skalldyr, peanøtter/nøtter og soya. Etter de 
seks ukene, vil vi systematisk innføre en og en av disse matvaregruppene i kosten igjen. Du 
vil få diettveiledning av en masterstudent i klinisk ernæringsfysiologi veiledet av en klinisk 
ernæringsfysiolog. 
 
Du er valgt ut til å få tilbud om å delta i studien fordi du er over 18 år og har fått diagnosen 
eosinofil øsofagitt. Det er kjent at «Six Food Elimination Diet» er effektiv hos barn og voksne 
med eosinofil øsofagitt, men dietten er enda ikke prøvd ut på den norske befolkning og vårt 
typiske kosthold. Vi ønsker også å finne mer ut om hva slags skade sykdommen gjør på 
spiserøret, ved å gjøre noen enkle målinger i spiserøret som ikke er gjort i denne 
sammenhengen tidligere. Vi vil derfor sammenligne måleresultater før og etter 
diettbehandling, for den enkelte pasient. Deretter starter vi gjeninnføring av matvarene som 
ble tatt bort, for å prøve å finne ut av hvilken matvare den enkelte reagerer på. Vi spør derfor 
om du vil være med på denne studien som kan vise oss om «Six Food Elimination Diet» og 
reintroduksjon er et effektivt behandlingsalternativ hos voksne med eosinofil øsofagitt.  
Studien utføres av overlegene Birgitte-Elise Emken og Jan Hatlebakk ved Haukeland 
Universitetssykehus som også er ansvarlig for prosjektet. Diettbehandlingen utføres av en 
masterstudent i klinisk ernæringsfysiologi og klinisk ernæringsfysiolog ved Haukeland 
Universitetssykehus. 
 
Hva innebærer studien? 
Studien innebærer at målinger som gastroskopier med biopsier (vevsprøve), blodprøver, 
prikktest, trykkmålinger og syremålinger blir gjort på deg, i tillegg til at du over en periode på 
seks uker vil gå på en eliminasjonsdiett, kalt «Six Food Elimination Diet». Det betyr at du må 
utelate seks matvarer/matvaregrupper fra kosten over en periode på seks uker. Når det 
kommer til selve diettbehandlingen, vil du få en detaljert oversikt over matvarer du ikke kan 
spise, samt alternativer til de matvarene du må kutte ut. Dersom du velger å delta i studien, vil 
du få en utdypende forklaring om hva som skal skje i studien. Du skal også fylle ut noen 
spørreskjemaer, som vil besvares ved oppstart av dietten, etter 3 uker og etter 6 uker. Dette 
kan gjøres hjemme og sendes til oss i posten. 





Fordelen ved å delta i studien er en mulig bedring av symptomer som svelgevansker og 
dermed mindre behov for behandling med medisiner, og mindre mulighet for bivirkninger av 




Det er mulig at du ikke får noen bedring av dietten og at prøvene du skal igjennom kan 
oppleves som ubehagelige. Komplikasjoner er svært sjeldne. I helt spesielle tilfeller kan en 
biopsi føre til blødning eller rift i spiserørsveggen. Dette er noe som kun er beskrevet hos 
færre enn 0,01% av pasientene. Sammenliknet med normal oppfølgning, vil deltakelse i 
prosjektet føre til en ekstra gastroskopi med biopsi, en ekstra trykkmåling og et ekstra 
oppmøte med poliklinisk samtale. Dietten vil ikke medføre noen bivirkninger. Dietten du skal 
følge fører sannsynligvis til at du må kutte ut en del matvarer du vanligvis spiser, noe som kan 
oppleves som vanskelig for noen. Sosiale sammenhenger kan også være en utfordring når 
man går på en diett.  
 
Hva skjer med prøvene og informasjonen om deg? 
Biopsier tatt ved gastroskopier og blodprøver vil lagres i en biobank som brukes til 
forskningen. All informasjon som registreres om deg skal kun brukes slik som beskrevet i 
hensikten med studien. Alle opplysninger og prøver i biobanken vil bli behandlet uten navn 
og fødselsnummer eller andre direkte gjenkjennende opplysninger. En kode knytter deg til 
dine opplysninger og prøver gjennom en navneliste. Det er kun autorisert personell knyttet til 
prosjektet som har adgang til navnelisten og som kan finne tilbake til deg. Prøvene vil 
ødelegges etter at nødvendige analyser er gjort. Ved publisering av resultatene vil identiteten 
din ikke komme fram.  
 
Frivillig deltakelse 
Det er frivillig å delta i studien. Du kan når som helst, uten å oppgi noen grunn, trekke ditt 
samtykke til å delta i studien. Dette vil ikke få noen konsekvenser for din videre behandling. 
Dersom du ønsker å delta, undertegner du samtykkeerklæringen på siste side av dette skrivet. 
Om du nå sier ja til å delta, kan du senere trekke tilbake ditt samtykke uten at det påvirker din 
øvrige behandling. Dersom du senere ønsker å trekke deg eller har spørsmål til studien, kan 
du kontakte student i klinisk ernæringsfysiologi Zoya Sabir (Telefon: 46 93 01 54), e-post: 
zsa087@student.uib.no). Eventuelt kan ansvarlig lege Birgitte-Elise Grinde Emken kontaktes 
på telefonnummer 55972130/31 eller på e-post biem@helse-bergen.no og/eller ansvarlig lege 
Jan Gunnar Hatlebakk på telefonnummer 977 07 817 eller på e-post jan.hatlebakk@helse-
bergen.no.  
 
Ytterligere informasjon om studien finnes i kapittel A – utdypende forklaring av hva 
studien innebærer.  
Ytterligere informasjon om biobank, personvern og forsikring finnes i kapittel B – 
personvern, biobank, økonomi og forsikring. 
Samtykkeerklæring følger etter kapittel B 
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Kapittel A – utdypende forklaring av hva studien 
innebærer 
 
Kriterier for deltakelse 
Vi spør deg om å delta i studien fordi du er over 18 år, du har fått diagnostisert eosinofil 
øsofagitt, og du har ubehag og symptomer. Diagnosen eosinofil øsofagitt har du fått på 
bakgrunn av biopsi av spiserøret, mens vi har utelukket refluks ved at du har negativ pH-
måling i spiserøret. 
 
Bakgrunnsinformasjon om studien 
Ikke alle med diagnostisert eosinofil øsofagitt opplever bedring av sykdommen ved 
behandling med prednisolon. Mange opplever også tilbakefall av symptomer etter endt 
behandling med prednisolon, og/eller bivirkninger ved langvarig bruk. «En Six Food 
Elimination Diet» har vist seg å være en effektiv behandling ved eosinofil øsofagitt, men det 
er ikke tidligere undersøkt om dietten har en effekt ved et nordisk kosthold. Dette vil være 
nyttig å kartlegge. Vi ønsker også å finne ut om hva slags skade sykdommen gjør på 
spiserøret, og vil derfor gjøre målinger som ikke tidligere er gjort i denne forbindelsen. Kan 
en «Six Food Elimination Diet» med gjenintroduksjon av matvarer være effektiv på 
betennelse i spiserøret, muskelsammentrekninger og bevegelse i spiserøret? 
 
Eosinofil øsofagitt er en sykdom som kan gi spiseproblemer hos barn og svelgevansker 
(dysfagi) hos voksne. I løpet av de siste ti årene har man stadig funnet ut mer om sykdommen. 
Blant annet vet vi i dag at eosinofil øsofagitt kommer av allergi mot mat- eller 
luftkomponenter. Likevel, flere utfordringer gjenstår. 
 
Ved en «Six Food Elimination Diet» med gjenintroduksjon utelates seks vanlige 
matvarer/matvaregrupper fra kosten i seks uker. Hensikten med dietten er å utelate det en 
reagerer på fra kosten. Deretter gjeninnføres en og en matvare, for på denne måten å finne ut 
hvilken matvare den enkelte reagerer på. Måleresultater før og etter diettbehandlingen, samt 
etter gjenintroduksjonen av matvaregruppene, vil fortelle om effekten av diettbehandlingen på 
sykdommen. Målingene vil være gastroskopier med biopsier. I tillegg vil det gjøres 
trykkmålinger og syremålinger, som vi forventer vil vise oss om bevegelse, 
muskelsammentrekninger og motstand i spiserøret vil bedres etter diettbehandling med 
gjenintroduksjon.  
 
Allergispesifikke og generelle blodprøver og prikktest 
Ved oppstart av studien, som er før oppstart av diettbehandlingen, skal det tas blodprøver og 
prikktest av deg. Dette er da snakk om allergispesifikke blodprøver, men også generelle 
blodprøver som viser ernæringsstatus. Blodprøvene og prikktesten tas på sykehuset i 
forbindelse med det første møtet. Det blir også tatt blodprøver av deg etter endt 
eliminasjonsdiett og etter endt gjenintroduksjon av matvaregrupper. Dette gjøres også på 
sykehuset i forbindelse med møter. Det er da de generelle blodprøvene som skal tas. 
 
Spørreskjemaer 
Du skal svare på 3 ulike spørreskjemaer, et skjema om symptomer av sykdommen (EEsAI), et 
skjema om livskvalitet (SF36) og et skjema som forteller hvordan du klarer å overholde 
dietten. Alle tre skjemaene skal besvares etter endt diettbehandling. Skjema om livskvalitet og 
symptomer skal i tillegg besvares før oppstart av dietten. Skjemaet om overholdelse av dietten 
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vil også besvares 3 uker ut i dietten (midt i diettbehandlingen). Det er da fullt mulig å besvare 
dette skjemaet hjemme og sende det til oss i posten.  
 
Tidsskjema – hva skjer og når skjer det? 
Du har blitt kontaktet og blitt spurt om å delta i studien. Dersom du er villig til å være med i 
studien, signerer du samtykkeskjemaet bakerst i dette skrivet. 
Du skal deretter møte opp på 5-7 møter, som alle vil finne sted på Haukeland 
Universitetssykehus på dagtid så langt det lar seg gjøre. 
 
1: Ved det første møtet, vil du få mer informasjon om hva studien innebærer og hva som skal 
skje framover. Det skal tas blodprøver og prikktest av dere før eller etter dette møtet. Det skal 
også tas en ny gastroskopi med biopsier av deg, så langt dette ikke er gjort relativt nylig. 
Resultatene fra gastroskopi med biopsier lagres i biobanken, sammen med resultatene fra 
blodprøvene.  
2: Ved det andre møtet vil det bli tatt trykkmåling (manometri/impedans) og syremåling (pH-
måling) av deg. Du vil også få utlevert skriftlig materiell i form av spørreskjemaer (SF36, 
symptomregistrering og overholdelse av dietten) som du må svare på underveis i studieløpet.  
3: Ved det tredje møtet vil du få en samtale med student i klinisk ernæringsfysiologi, før 
oppstart av «Six Food Elimination Diet» som skal vare i de neste seks ukene. Du vil også få 
utlevert skriftlig informasjon om dietten. Dette er detaljert informasjon om matvarer du må 
fjerne fra kosten i de neste seks ukene og alternativer til disse matvarene. Ved dette møtet skal 
du også levere inn skjema om livskvalitet (SF36) og symptomregistreringsskjema til 
studenten i klinisk ernæringsfysiologi. Skjemaene angir hvor plaget du er av eosinofil 
øsofagitt og hvordan dette påvirker din livskvalitet.  
3 uker ut i diettbehandlingen skal du fylle ut et skjema om overholdelse av dietten. Det utfylte 
skjemaet sendes i posten. 
Ved spørsmål og problemer med dietten har du mulighet til å kontakte student i klinisk 
ernæringsfysiologi på telefon eller e-post (se kontaktinformasjon på andre side). Du kan 
eventuelt også kontakte de ansvarlige legene. 
4: Det fjerde møtet blir etter endt elimsinasjonsdiett, hvor det nå skal testes for effekt av 
dietten. Det vil tas ny gastroskopi med biopsier, som vil komme i tillegg ved deltakelse i 
forskningsprosjektet, sammenliknet med normal oppfølgning ved Haukeland 
Universitetssykehus. Det skal også tas blodprøver av deg ved dette møtet. Alle 
måleresultatene vil lagres i biobanken. Ved dette møtet skal igjen de 3 skjemaene (om 
livskvalitet, symptomregistrering og overholdelse av dietten) tas med og leveres inn ferdig 
utfylt. 
5: Ved det femte møtet, skal det gjøres trykkmåling slik du gjorde før diettbehandlingen 
startet. Denne trykkmålingen vil også komme i tillegg ved deltakelse i forskningsprosjektet, 
sammenliknet med normal oppfølgning ved Haukeland Universitetssykehus. 
Dersom du opplever en effekt av dietten, sett ved resultatene fra gastroskopi med biopsier i 
etterkant av diettbehandlingen, vil du ha 2 møter til som også vil finne sted på Haukeland 
Universitetssykehus. En klinisk ernæringsfysiolog vil være tilstede ved det fjerde møtet, som 
vil informere om gjenintroduksjon av matvarer, hvor en og en av de utelatte 
matvarene/matvaregruppene nå blir gjenintrodusert med 14 dagers mellomrom. Under selve 
gjenintroduksjonen vil det ikke bli oppsatte møter ved Haukeland Universitetssykehus for 
hver enkelt matvare/matvaregruppe som gjenintroduseres. I stedet avtales for den enkelte 
enten et personlig møte eller møte pr. telefon for hver gjenintroduksjon. Etter 
gjenintroduksjonen skal du møte opp på Haukeland Universitetssykehus for de to siste 
møtene.  
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6: Det sjette møtet vil være 14 dager etter avsluttet gjenintroduksjon av 
matvarer/matvaregrupper. Da skal det tas en ny gastroskopi med biopsier og nye blodprøver. 
7: Ved det syvende og siste møtet, skal det gjøres syremåling og trykkmåling slik du gjorde 
før og etter diettbehandlingen. 
Dersom du ikke opplever noen effekt av diettbehandlingen, sett ved resultatene av biopsiene 
ved gastroskopi etter endt eliminasjonsdiett, vil det ikke være nødvendig med systematisk 
gjenintroduksjon av de matvarene du har utelatt fra kosten, og de to siste møtene ved 
Haukeland Universitetssykehus vil falle bort.  
 
Alternative prosedyrer dersom du ikke velger å delta i studien 
Dersom du underveis i studien ønsker å avslutte diettbehandlingen og/eller ikke ønsker å delta 
i studien, vil du få tilbud om tradisjonell behandling med medisiner og oppfølgning på 
poliklinikken på vanlig måte. Om du ønsker å trekke deg kan du ta kontakt når som helst. Da 
vil du bli invitert til en samtale, og eventuelle problemer vil bli diskutert. Du har selvfølgelig 
fortsatt rett til å slutte i studien når som helst uten å oppgi grunn. 
 
Studiedeltakerens ansvar 
Som deltaker i denne studien ber vi om at du setter deg inn i informasjon om prøver og 
målinger, samt følger dietten. Tid og dato for møtene og prøvene skal avtales slik at det passer 
for begge parter. Med tanke på at det noen ganger vil være flere studiedeltakere og behandlere 
ved et møte, ber vi om at du er fleksibel på tid og dato for møtene og prøvene som skal bli 
tatt. Du må også møte opp til avtalt tid, eventuelt ringe i god tid dersom timen ikke passer. Du 
har også ansvar for å fylle ut skjemaene som avtalt, ta dem med på møtene og sende dem i 
posten før avtale frister. På det første møtet med oss vil du få mer nøyaktig informasjon enn 
det som står i dette skrivet.  
 
Endringer i planen 
Dersom det skjer endringer i planen eller ved tidligere avslutning av dietten, vil du bli 
informert om dette så raskt som mulig. Du vil også bli informert dersom ny informasjon blir 
tilgjengelig som kan føre til at du ikke lenger ønsker å delta i studien. Dersom det oppstår en 
uforutsett hendelse som gjør at studien må avsluttes, vil du bli kontaktet snarest mulig.  
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Kapittel B – personvern, biobank, økonomi og forsikring 
Personvern 
Opplysninger som registreres om deg er informasjon om symptomer og livskvalitet fra 
forskjellige skjemaer som du vil fylle ut. Resultater fra gastroskopier med biopsier, 
blodprøver og andre målinger vil også bli registrert. Kontaktinformasjon (navn og 
telefonnummer) om deg vil bli lagret. Det er kun vi som holder på med studien som har 
tilgang til opplysninger om deg. Disse vil bli lagret innelåst.   
 
Biobank 
Vi har en biobank for lagring av blodprøver og biopsier fra gastroskopi.  
 
Utlevering av materiale og opplysninger til andre 
Hvis du sier ja til å delta i studien, gir du også ditt samtykke til at prøver og avidentifiserte 
opplysninger brukes til denne studien ved Haukeland Universitetssykehus. Avidentifiserte 
opplysninger skal ikke sendes til andre foretak eller foretak i andre land. 
 
Rett til innsyn og sletting av opplysninger om deg og sletting av prøver 
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som er 
registrert om deg. Du har videre rett til å få korrigert eventuelle feil i de opplysningene vi har 
registrert. Dersom du trekker deg fra studien, kan du kreve å få slettet innsamlede prøver og 
opplysninger, med mindre opplysningene allerede er inngått i analyser eller brukt i 
vitenskapelige publikasjoner. 
 
Økonomi og Haukeland Universitetssykehus’ rolle 
Studien er finansiert gjennom driftsmidler ved Helse Bergen og forskningsmidler fra 
gastroenterologisk seksjon ved Klinisk Institutt 1 ved Universitetet i Bergen. De vil bidra med 
personell til analyser av blodprøver. Det er ingen mulige interessekonflikter.  
 
Forsikring 
Forsikringsordningen som gjelder er pasientskadeerstatning, idet du som deltaker er under 
behandling ved Haukeland Universitetssykehus.   
 
Informasjon om utfallet av studien 
Du har som deltaker i studien rett til å få informasjon om utfallet av studien når dette er klart. 
En sluttrapport vil sendes til deg. 
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Samtykke til deltakelse i studien 
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Appendix 5: SF-36 questionnaire 
 
SF-36 Norsk versjon 
 
SF-36® Health Survey© 1988, 2002 by JE Ware, Jr., MOT, Health Assessment Lab, 
QualityMetric Incorporated – All rights reserved 
SF-36® is a registered trademark of the Medical Outcomes Trust (MOT) 
 
 
Vi spør deg her om hvordan du opplever din egen helse. Vi ønsker å vite hvordan du føler deg 
og hvordan du mestrer dine vanlige aktiviteter. Vær snill å svare på alle spørsmål. Noen av 
spørsmålene ligner på hverandre, men alle er forskjellige. Ta deg tid til å lese spørsmålene 
nøye og svar med et kryss for det alternativ som du velger! 
 














   
2.  Sammenlignet med for ett år siden, hvordan vil du si at helsen din stort sett er nå? 
Mye bedre 
nå enn for 




nå enn for 
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3.  De neste spørsmålene handler om gjøremål som du kanskje utfører i løpet av en vanlig 



















meg ikke i 
det hele tatt 
Anstrengende aktiviteter, som å løpe, løfte tunge 
gjenstander, delta i anstrengende idrett 
○ ○ ○ 
Moderate aktiviteter, som å flytte et bord, støvsuge, 







Løfte eller bære en handlekurv 
○ ○ ○ 
Gå opp trappen flere etasjer 
○ ○ ○ 
Gå opp trappen en etasje 
○ ○ ○ 
Bøye deg eller sitte på huk 
○ ○ ○ 
Gå mer enn to kilometer 
○ ○ ○ 
Gå noen hundre meter 
○ ○ ○ 
Gå hundre meter 
○ ○ ○ 
Vaske deg eller kle på deg 
○ ○ ○ 
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4. I løpet av de siste fire ukene, har du hatt noen av følgende problemer i ditt arbeid eller i 


















Har du redusert tiden du har brukt på 
arbeidet ditt eller andre aktiviteter 
○ ○ ○ ○ ○ 
Har du utrettet mindre enn du hadde 
ønsket 
○ ○ ○ ○ ○ 
Har du vært hindret i visse typer arbeid 
eller andre aktiviteter 
○ ○ ○ ○ ○ 
Har du hatt vansker med å utføre 
arbeidet ditt eller andre aktiviteter (for 
eksempel fordi det krevde ekstra 
anstrengelser) 
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5.   I løpet av de siste fire ukene, har du hatt følelsesmessige problemer som har ført til 
vanskeligheter i ditt arbeid  eller i andre av dine daglige gjøremål (for eksempel fordi du har 


















Har du redusert tiden du har brukt 
på arbeidet ditt eller andre aktiviteter 
○ ○ ○ ○ ○ 
Har du utrettet mindre enn du hadde 
ønsket 
○ ○ ○ ○ ○ 
Har du ikke arbeidet eller utført andre 
aktiviteter like nøye som vanlig 





6.   I løpet av de siste 4 ukene, i hvilken grad har din fysiske helse eller følelsesmessige 


























      ○ 
 
  

































8. I løpet av de siste 4 ukene, hvor mye har smerter påvirket ditt vanlige arbeid (gjelder 
























9.   De neste spørsmålene handler om hvordan du har følt deg og hvordan du har hatt det 
de siste 4 ukene. For hvert spørsmål, vennligst velg det svaralternativet som best 
















følt deg full av tiltakslyst? ○ ○ ○ ○ ○ 
følt deg veldig nervøs? ○ ○ ○ ○ ○ 
vært så langt nede at ingenting 
har kunnet muntre deg opp? ○ ○ ○ ○ ○ 
følt deg rolig og harmonisk? ○ ○ ○ ○ ○ 
hatt mye overskudd? ○ ○ ○ ○ ○ 
følt deg nedfor og trist? ○ ○ ○ ○ ○ 
følt deg sliten? ○ ○ ○ ○ ○ 
følt deg glad? ○ ○ ○ ○ ○ 
følt deg trøtt? ○ ○ ○ ○ ○ 





10.   I løpet av de siste 4 ukene, hvor mye av tiden har din fysiske helse eller følelsesmessige 






































Det virker som jeg blir litt lettere syk enn 
andre 
○ ○ ○ ○ ○ 
Jeg er like frisk som de fleste jeg kjenner ○ ○ ○ ○ ○ 
Jeg forventer at min helse vil bli dårligere ○ ○ ○ ○ ○ 
Min helse er utmerket ○ ○ ○ ○ ○ 
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Kostholdet ditt siste 12 måneder 







Hvis «aldri», hvorfor:  
□ Allergi/overfølsomhet 
□ Liker ikke 








Hvis «aldri», hvorfor:  
□ Allergi/overfølsomhet 
□ Liker ikke 
□ Andre grunner (forklar:_____________________________) 
 






Hvis «aldri», hvorfor:  
□ Allergi/overfølsomhet 
□ Liker ikke 
□ Andre grunner (forklar:_____________________________) 
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d) Unngår du mat som inneholder melk eller melkeprodukter?  
□ Ja, alltid 
□ Ja, som regel 
□ Nei 
 






Hvis «aldri», hvorfor:  
□ Allergi/overfølsomhet 
□ Liker ikke 
□ Andre grunner (forklar:_____________________________) 
 
f) Unngår du mat som inneholder egg?  
□ Ja, alltid 
□ Ja, som regel 
□ Nei 
 






Hvis «aldri», hvorfor:  
□ Allergi/overfølsomhet 
□ Liker ikke 
□ Andre grunner (forklar:_____________________________) 
 
h) Unngår du mat som inneholder hvete?  
□ Ja, alltid 
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i) Unngår du mat som inneholder gluten?  
□ Ja, alltid 
□ Ja, som regel 
□ Nei 
 






Hvis «aldri», hvorfor:  
□ Allergi/overfølsomhet 
□ Liker ikke 
□ Andre grunner (forklar:_____________________________) 
 






Hvis «aldri», hvorfor:  
□ Allergi/overfølsomhet 
□ Liker ikke 
□ Andre grunner (forklar:_____________________________) 
 






Hvis «aldri», hvorfor:  
□ Allergi/overfølsomhet 
□ Liker ikke 
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Hvis «aldri», hvorfor:  
□ Allergi/overfølsomhet 
□ Liker ikke 
□ Andre grunner (forklar:_____________________________) 
 






Hvis «aldri», hvorfor:  
□ Allergi/overfølsomhet 
□ Liker ikke 
□ Andre grunner (forklar:_____________________________) 
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Dette er en testdiett som skal følges i noen uker mens du deltar i et forskningsprosjekt om 
eosinofil øsofagitt. Rådene i dette skrivet vil ikke nødvendigvis passe for personer med påvist 
allergi mot de samme matvarene/matvaregruppene (henholdsvis melk, egg, hvete/gluten, 
fisk/skalldyr, soya, og/eller nøtter/peanøtter).  
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UNNGÅ VELG I STEDET 
MELK OG MELKEPRODUKTER 
Alle typer melk (fra ku, geit eller andre pattedyr). 
 
Yoghurt 
Fløte, rømme, creme fraiche, kesam. 
Alle typer ost (brun og hvit). Prim. 
Iskrem. 
ERSTATNING FOR KUMELKSPRODUKTER 
Matlaging: Havremelk, rismelk, vann, kraft, 
buljong, fruktjuice. 
Fruktpureer, smoothie. 
Fløteerstatning (havrebasert). Kokosmelk. 
Wilmersburger (Osteerstatning).  
Saftis uten sjokoladetrekk. Slush. Risbasert iskrem 
(Rice Dream)*.  
MATFETT 
Meierismør, margarin, lettmargarin. 
 
MATFETT 
Soft Spesial margarin uten melk og soya (blå). 
Matoljer (alle typer bortsett fra nøtteoljer og  
soyaolje). 
EGG 
Egg i alle former (både plommen og hviten). 
 
ERSTATNING FOR EGG 
Baking: Eggerstatning*(f eks Orgran No Egg eller 
Egg Replacer), linfrø-avkok eller bakepulver kan 
erstatte egg. 
KORNVARER 
Hvete, rug, bygg, spelt og vanlig havre (mel, gryn, 















Mel og gryn av ris, mais, bokhvete, hirse, quinoa, 
teff, amarant. 
Ren, glutenfri havre. 
Glutenfrie melblandinger uten melk/egg/soya:  
• Toro glutenfrie melblandinger (grov og lys) 
• Jyttemjøl (alle typer) 
• Semper Fin mix og Grov mix 
• Finax Gluten & mjölkfri melblandinger 
Potetmel, maizena. 
Polentagryn, sagogryn. 
Pofiber*, Fiber Husk*; Fibrex*, linfrø, psyllium. 
Puffet ris, glutenfri corn flakes*,  Finax Glutenfri 
Frukt Müsli*, Semper Multimüsli*.  
Glutenfri makaroni/spaghetti uten egg/soya (f.eks. 
fra Schär/Semper). Ris, risnudler. 
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BRØD OG ANDRE BAKERVARER 
Vanlig brød, rundstykker, knekkebrød, kjeks, 
boller, kaker, vafler, pannekaker osv. 
 
 
BRØD OG ANDRE BAKERVARER 
Glutenfritt brød/bakverk som er fritt for melk, egg, 
soya og nøtter (f.eks. de fleste produktene fra Fria, 
gluten- og melkefrie brød fra Brisk, Wasa gluten- 
og laktosefritt knekkebrød, mange sorter brød og 
knekkebrød fra Semper) 
Riskjeks, maiskjeks. 
 Tacoskjell.  
ØL 
Glutenholdig øl, med og uten alkohol (vørterøl). 
ØL 
Glutenfritt øl (eks: Ringnes Lite, Estrella Galicia, 
Estrella Daura, Lammsbräu Glutenfrei, Against the 
Grain, Greens Blonde) 
Ingefærøl (brus). 
* Selges i nettbutikker, helsekostforretninger og velassorterte dagligvareforretninger. 
 
UNNGÅ VELG I STEDET 
KJØTT 
Middagsmat: Vanlige pølser, kjøttkaker og 







Pålegg: Leverpostei, servelat og annet kjøttpålegg 
som inneholder melk, hvetemel eller soya. 
KJØTT 
Middagsmat: All slags rent kjøtt (f eks 
kalv/storfe, lam/får, svin, vilt, kylling/høne, 
kalkun), kjøttdeig, medisterdeig, skinke på boks, 
hjemmelagede kjøttkaker og kjøttboller (lag  
farse av kjøttdeig, potetmel, vann, salt og 
krydder). Gilde Go’ og Mager pølser og 
kjøttkaker. Leif Vidar Wienerpølser og 
Grillpølser (kjøpt i butikk). 
Pålegg: De fleste kjøttpålegg som kokt skinke, 
bankekjøtt, spekekjøtt, fårepølse, salami, men 
sjekk ingredienslisten. Gilde Go’og mager: 
Leverpostei og Servelat. Rester av middagsmat 
(kjøttkaker, stek). 
FISK OG SKALLDYR 
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POTETER OG GRØNNSAKER 
Potetmos, stuinger og andre potet- eller 
grønnsakretter hvor egg, mel eller melk inngår. 
 
POTETER OG GRØNNSAKER 
Poteter og grønnsaker i ren form. 
FRUKT OG BÆR 
Mandler og nøtter av alle slag.  
 
FRUKT OG BÆR 
Alle andre typer frukt og bær.  
ANNET 
Sauser og supper: Sauser og supper som 
inneholder melk, egg, soya og/eller gluten/hvete. 
Majones, remulade, majonesbaserte dressinger. 
 
Pålegg: Nugatti, Hapå, peanøttsmør etc. 
Italiensk salat og andre majonessalater.  
 
Snacks: Ostepop, peanøtter, diverse chips-typer. 
Desserter: Puddinger, fromasjer, iskrem. 
 
Søtsaker: Sjokolade, karameller, marsipan. Lakris 
og fylte drops kan inneholde hvete. 
ANNET 
Sauser og supper: Hjemmelagede sauser og 
supper (jevnet med maisenna). Sjysaus. Enkelte 
grønnsaksauser til pasta og ris på glass (sjekk 
ingredienslisten). Fransk dressing (olje/eddik). 
Pålegg: Kjøttpålegg, Gilde Go’ og mager 
leverpostei, Streich smørepålegg*, syltetøy, 
honning, skiver av frukt og grønnsaker. 
Snacks: Maarud potetgull med salt. 
Desserter: Kompotter, hermetisk frukt, fruktsalat,  
gelé, saftis. 
Søtsaker:  Pastiller, drops, seigmenn, vingummi, 
skumgodter, marshmallows, rosiner.  
Les innholdsfortegnelsen!  
* Selges i helsekostforretninger og enkelte velassortert dagligvareforretninger.  




Mange typer ferdigmat inneholder melk, egg, fisk, skalldyr, glutenholdige korn, peanøtter, 
nøtter og/eller soya i større eller mindre mengder. Det er derfor viktig å lese 
varedeklarasjonen nøye. Produsenten er pålagt å oppgi alle ingredienser og forekomst av noen 
av de nevte matvarene skal merkes tydelig. 
 
Mat uten varedeklarasjon (f.eks. i ferskvaredisk, restaurant) kan inneholde uventede 
ingredienser. Spør alltid om innholdet og bruk ikke matvarer med ukjent sammensetning! 
 
Melk kan deklareres som 
• melk, tørrmelk eller melkepulver 
• melkeprotein 
• myse, mysepulver 
• fløte, rømme, creme fraiche, fløtepulver 
• yoghurt 
• ost, ostepulver, kvarg, cottage cheese, kesam 
 
Fett brukt til steking og baking (margarin, smør m.m.) inneholder svært ofte melk. 
 






Majones og majonesbaserte dressinger innholder nesten alltid egg. 
 
Gluten kan deklareres som 
• hvete, rug, bygg, havre, spelt 
• hvetemel, hvetekli, hvetekim, hveteprotein, puffet hvete 
• durumhvete, makaroni, pasta 
• semulegryn 
• couscous, bulgur 
• rugmel  
• byggmel, byggryn 
• havremel, havregryn, havrekli, puffet havre  
• triticale (en krysning mellom hvete og rug) 
• spelt, dinkel, emmerhvete (gamle hvetesorter) 
 
Strøbrød og griljering/panering inneholder som regel gluten. Godt renset hvetestivelse er 
tillatt ingrediens i produkter som er merket ”glutenfri”. Havre som er merket ”glutenfri” kan 
også inngå i glutenfri kost. Hvetestivelse i glutenfrie produkter og glutenfri havre er produkter 
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Alt som ifølge ingredienslisten inneholder soya er ikke tillatt, med unntak av soyalecitin 
(E322). 
 









• Peanøtt (jordnøtt) 
 
Tilsetningsstoffer 
Dersom tilsetningsstoffene som er brukt i en matvare inneholder eller er utvunnet av melk, 
egg, hvete/glutenholdig kornsort, fisk, skalldyr, soya, peanøtter eller nøtter, skal dette framgå 
av varedeklarasjonen. 
 
Forurensing/kontaminering av matvarer 
Bearbeidede matvarer kan i blant inneholde små mengder tørrmelk, eggepulver, nøttestøv e.l. 
uten at dette framgår av innholdsdeklarasjonen. Det dreier seg da om en forurensing, som kan 
skyldes at mange ulike produkter tilvirkes i samme lokale eller med samme utstyr. I slike 
tilfeller velger enkelte produsenter å opplyse om at matvaren kan inneholde spor av melk, 
egg, nøtter etc. I fasteperioden er matvarer merket med «spor av» tillatt. 
  




Frokost, lunsj og kvelds 
• Havregrøt (tilberedt av glutenfrie havregryn og vann eller havremelk) 
• Frokostblanding (Finax glutenfri frukt müsli, Semper Multimüsli eller Nestle Gluten 
Free Corn Flakes) med havremelk eller rismelk 
• Hjemmelaget müsli av glutenfrie havregryn/cornflakes, rosiner og annen tørket frukt 
• Ristet brød med Soft spesial margarin og syltetøy/marmelade 
• Varme rundstykker med diverse pålegg (se forslag) 
• Hjemmelagde eller kjøpte knekkebrød med pålegg 
• Sprøstekt bacon med tomatbønner 
• Middagsrester 
• Salat  
 
Brød/bakevarer/knekkebrød: brød fra Fria, frossenvarer fra Brisk, brød fra Schär, Semper 
brød eller melblandinger, Semper Grovknäcke (eks rosmarinknäcke, havreknäcke), Wasa 
gluten- og laktosefritt knekkebrød 
 
Pålegg: De fleste kjøttpålegg (eks kokt skinke, kalkunfilet), produkter fra Gilde Go` og mager 
(servelat, leverpostei), syltetøy, honning, Wilmersburger-ost, middagsrester 
  








• Taco (uten ost og rømme) 
• Lasagne (glutenfri lasagne, melkeerstaning og Wilmersburger-ost) 
• Pizza (laget med glutenfri bunn og Wilmersburger-ost) 
 
 
Dessert og kjeks/snacks  
• Hildes sjokoladekake/gulrotkake (www.hildekaken.no)  
• Gele med freia vaniljesaus til koking (tilberedes med melkeerstatning) 
• Salt potetchips 
• Spesialsjokolade (melkefri sjokolade) 
• Gelesnop 
• Semper Cookie-O`s 
• Frukt (fruktsalat/fruktkompott) 
• Smoothie 









Toro:  Lett bearnaisesaus (tilberedes med melkeerstatning) 
  Glutenfri brun saus eller glutenfri hvit saus 
  Glutenfri tomatsuppe 
  Glutenfri blomkålsuppe (tilberedes med melkeerstatning) 




Eksempler på egnede produkter. 
Findus: Mexican chicken (dypfryst) 
Fjordland: Lys lapskaus (kjølevare) 
  Ertesuppe med bacon (kjølevare) 
  Fårikål med poteter (kjølevare) 
Fria:  Pizza Prosciutto (dypfryst) 
  Pizza Margherita (dypfryst) 
Toro:  Thai panang curry kylllingryte (kjølevare) 




Nettstedene www.allergikokken.no og www.allergimat.no  
 




Kost uten melk, egg, fisk og glutenholdige kornsorter kan bli energifattig og gi for lite av 
enkelte næringsstoffer - spesielt vitamin B2 (riboflavin), vitamin D, kalsium, jern, jod, selen, 
omega-3-fettsyrer og fiber.  
 
Anbefalte tilskudd: 1000 mg kalsium (2-4 tygge-eller svelgetabletter)* 
   1 multivitamin- og mineraltablett (f.eks. Nycomed Multi) 
   Tran eller omega-3 
* Uten vitamin D dersom du tar tran og/eller vitamintilskudd med vitamin D 
 
 
Ved behov for næringsdrikk fra apotek kan følgende produkter brukes: 
• ProvideXtra drink (juiceliknende drikk, smaker: eple, solbær, appelsin & ananas) 
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Appendix 8: Two-week menu suggestion and recipes  
 




• Frokost: Havregrøt med banan (av glutenfrie havregryn, laget på vann, med 
havremelk) 
• Lunsj: Knekkebrød (eks. Semper) med smør (Soft blå), div. pålegg (kokt skinke, 
kalkunfilet, spekeskinke, og div. grønnsaker (agurk, paprika o.l.) 
• Middag: Spagetti (glutenfri) bolognese  
• Kvelds: Brødskiver med smør (Soft blå), div. pålegg og grønnsaker (agurk, paprika) 
• Mellommåltid: Gulrot (-røtter) 
• Husk å ta kosttilskudd ☺  
 
TIRSDAG 
• F: Frokostblanding (eks. Gluten Free Corn Flakes med havremelk/rismelk) 
• L: Middagsrester 
• M: Ovnsbakt kyllingfilet, potetbåter og ovnsstekte grønnsaker (løk, rotgrønnsaker), ris 
• K: Knekkebrød med smør (soft blå), div. pålegg og div. grønnsaker (agurk, paprika) 
• MM: Smoothie 
• Husk å ta kosttilskudd ☺  
 
ONSDAG 
• F: Müsli (hjemmelaget eller Semper Multimüsli, med havremelk/rismelk) 
• L: Knekkebrød med smør (soft blå) div. pålegg og div. grønnsaker (agurk, paprika) 
• M: Wok med strimlet svinekjøtt 
• K: Brødskiver med smør (soft blå) div. pålegg og div. grønnsaker (agurk, paprika) 
• MM: Banan(er) og pære(r) 
• Husk å ta kosttilskudd ☺  
 
TORSDAG 
• F: Havregrøt med blåbær (av glutenfrie havregryn, laget på vann, med havremelk) 
• L: Middagsrester 
• M: Suppe 
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• K: Rundstykker (eks fra Schär) med smør (soft blå), div. pålegg og div. grønnsaker 
(eks agurk, paprika) 
• MM: Pære(r) og eple(r) 
• Husk å ta kosttilskudd ☺  
 
FREDAG 
• F: Frokostblanding (eks. Gluten Free Corn Flakes med havremelk/rismelk) 
• L: Knekkebrød med smør (soft blå), div. pålegg og div. grønnsaker (agurk, reddik) 
• M: Taco (uten tacolefser, ost og rømme) 
• K: Ristet brød med smør (soft blå), div. pålegg og div grønnsaker (agurk, paprika) 
• MM: Eple(r) og banan(er) 
• Husk å ta kosttilskudd ☺  
 
LØRDAG 
• F: Varme rundstykker med smør (soft blå) div. pålegg og div grønnsaker (agurk, 
reddik) 
• L: Knekkebrød med smør (soft blå) div. pålegg og div grønnsaker (agurk, paprika) 
• M: Pizza (laget med glutenfri bunn og Wilmerburger-ost) 
• K: Müsli (hjemmelaget, Semper Multimüsli, med havremelk/rismelk) 
• MM: Smoothie 
• Husk å ta kosttilskudd ☺  
 
SØNDAG 
• F: Sprøstekt bacon med tomatbønner, agurk og ristet, glutenfritt brød 
• L: Müsli (hjemmelaget, Semper Multimüsli, med havremelk/rismelk) 
• M: Lasagne m/salat (glutenfri lasagne/aubergine/squash, melkeerstatning, 
Wilmersburger-ost) 
• K: Knekkebrød med smør (soft blå), div. pålegg og div. grønnsaker (agurk, reddik) 
• MM: Salat 















• F: Havregrøt med banan (av glutenfrie havregryn, laget på vann, med havremelk) 
• L: Pizzarester 
• M: Spagetti (glutenfri) bolognese 
• K: Knekkebrød med smør (soft blå), div. pålegg og div. grønnsaker (agurk, reddik) 
• MM: Smoothie (hjemmelaget eller kjøpt) 
• Husk å ta kosttilskudd ☺  
 
TIRSDAG 
• F: Knekkebrød med smør (soft blå), div. pålegg og div. grønnsaker (agurk, reddik) 
• L: Middagsrester 
• M: Kjøttkaker (Gilde go’ og mager eller hjemmelagde), kokte poteter og kokte 
grønnsaker 
• K: Müsli (hjemmelaget eller Semper Multimüsli, med havremelk/rismelk) 
• MM: Pære(r) og nektarin(er) 
• Husk å ta kosttilskudd ☺  
 
ONSDAG 
• F: Frokostblanding (eks. Gluten Free Corn Flakes med havremelk/rismelk) 
• L: Salat 
• M: Kyllingwok  
• K: Rundstykker med smør (soft blå), div. pålegg og div. grønnsaker (agurk, tomat, 
reddik) 
• MM: Gulrot(-røtter) 
• Husk å ta kosttilskudd ☺  
 
TORSDAG 
• F: Havregrøt med blåbær (av glutenfrie havregryn, laget på vann, med havremelk) 
• L: Middagsrester 
• M: Suppe 
• K: Knekkebrød med smør (soft blå), div. pålegg og div. grønnsaker (agurk, reddik) 
• MM: Banan(er) og nektarin(er) 
• Husk å ta kosttilskudd ☺  
 




• F: Frokostblanding (eks. Gluten Free Corn Flakes med havremelk/rismelk) 
• L: Brødskiver med smør (soft blå), div. pålegg og div. grønnsaker (agurk, tomat) 
• M: Hjemmelaget hamburger (glutenfritt hamburgerbrød, uten dressing og ost) 
• K: Salat 
• MM: Eple(r) og pære(r) 
• Husk å ta kosttilskudd ☺  
 
LØRDAG 
• F: Varme rundstykker med smør (soft blå), div. pålegg og div grønnsaker (agurk, 
tomat) 
• L: Müsli (hjemmelaget, Semper Multimüsli, med havremelk/rismelk) 
• M: Taco (uten tacolefser, ost og rømme) 
• K: Knekkebrød med smør (soft blå), div. pålegg og div grønnsaker (agurk, reddik) 
• MM: Smoothie  
• Husk å ta kosttilskudd ☺  
 
SØNDAG 
• F: Sprøstekt bacon med tomatbønner, agurk og ristet, glutenfritt brød med smør (Soft 
blå) 
• L: Knekkebrød med smør (soft blå) div. pålegg og div grønnsaker (tomat, reddik) 
• M: Kyllingsalat med ristet, glutenfritt brød med smør (Soft blå) 
• K: Frokostblanding (eks. Gluten Free Corn Flakes med havremelk/rismelk) 
• MM: Banan(er) og eple(r) 
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Havregrøt av glutenfrie havregryn, laget på vann – 2 porsjoner 
 
- 3 dl vann 
- 1,5 dl glutenfrie havregryn 
 
Serveres med et smørøye, banan, blåbær, sukker, kanel, havremelk o.l. etter ønske  
 
Brød (1) – 1 brød 
 
- 50 g gjær 
- 4 dl melkeerstatning 
- ½ dl flytende margarin (Soft blå) 
- 1ss fiberhusk 
- 1ss lys sirup 
- 2 dl pofiber 
- 1 ts salt 
- 5 dl grov, glutenfri melmiks (eks fra Semper) 
- 1ts anis 
Smuldre gjæren i en bakebolle. Varm melken og margarin til 37 C, og hell over gjæren. Rør 
til gjæren er oppløst. Tilsett fiberhusk og la det stå og svelle i 10 minutter. Ha i resten av 
ingrediensene og arbeid deigen godt sammen. La deigen heve under plast i bakebollen i 30 
minutter. Dryss melmiks på bakebordet, elt deigen og form den til et brød som legges på 
bakepapirkledt bakeplate. Heves i 30 minutter. Stek brødet på nederste rille i ca 45 min på 
200 C 
Tips: ønsker du sprø skorpe kan du sette inn en skål med 2 dl vann nederst i ovnen. 
Dampen som frigjøres under stekingen gjør at brødskorpen blir sprøere.  
Tips: man kan også lage rundstykker av denne oppskriften. 
 
Brød (2) 
- 1L vann 
- 50g gjær 
- 2ss rapsolje til baking 
- 2ss fiberhusk 
- 1ss honning (kan sløyfes) 
- 2ts salt 
- 1-2 poteter, ca. 150g moste, kokte poteter 
- 100 g glutenfrie havregryn 
- Ca. 750g grov, glutenfri melblanding (eks. Semper grov mix) 
 
Ha fingervarmt vann i en bakebolle, tilsett olje og fiberhusk, rør om, og la svelle i ca. 10 
minutter. Tørrgjær tilsettes med det tørre, fersk gjær løses opp i den fingervarme væsken. 
Elt inn glutenfritt mel, havregryn, mosede poteter og salt. Bruk kjøkkenmaskin med 
eltekrok. Denne deigen skal være løsere enn en tradisjonell deig med hvetemel. Fordel 
deigen i smurte brødformer, eller form den med en slikkepott til et rundt brød på 
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stekebrettet. Dekk med klede, og la deigen heve 40-50 minutter. Stek ved 200 grader på 
nederste rille i ca. 45 minutter.  
Tips: man kan også lage rundstykker av denne oppskriften.  
 
Hjemmelaget müsli 
- Glutenfrie havregryn 
- solsikkefrø 
- Rosiner 
- Tørket frukt, eks aprikos, banan 
- Glutenfrie corn Flakes 
Rist havregryn og solsikkefrø i en varm og tørr stekepanne. Rør hele tiden. Bland inn andre 
(ønskede) ingredienser. Serveres gjerne med fersk frukt og/eller bær og melkeerstatning. 
 
Spagetti Bolognese – 4 porsjoner 
 
- 400g karbonadedeig 
- 2ss margarin eller olje til steking 
- 1 stk finhakket gulrot 
- 1 stk finhakket løk 
- 2 stk finhakket stilkselleri (stangselleri) 
- 2ss tomatpuré 
- 1 boks hermetiske tomater 
- 1ts salt 
- ½ ts pepper 
- 400g spagetti (glutenfri) 
- Ingredienser til en salat ved siden av (isbergsalat, agurk, paprika/reddiker) 
 
Ha margarin eller olje i en varm stekepanne. Stek kjøttdeig i biter. Ha i grønnsaker, 
tomatpurè og hermetisk tomat. Kok opp og la denne sausen småkoke i 15-20 minutter. 
Smak til med salt og pepper. Kok glutenfri spagetti i en kjele med lettsaltet vann etter 
anvisning på pakken. Server frisk salat til.  
 
 
Kjøttkaker Gilde go’ og mager 
 
- Lag etter anvisning på pakken, kok poteter og grønnsaker (gulrot, kål, erter) 
 
Tips: server med glutenfri, brun saus fra Toro eller hjemmelaget brun saus (jevnet med 
maisenna) 
 
Wok med strimlet svinekjøtt – 2 porsjoner 
- 1 gulrot, ½ rødløk, 1 paprika og purre eller frossen wokblanding fra eks. 
Findus/Eldorado 
- 250g strimlet svinekjøtt stekes 
- 2ss olje 
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- Søt chilisaus, fra eks. Eldorado 
- Kokt ris 
Grovriv gulrot, skjær paprika i strimler og purre i ringer. Varm oljen i woken til det ryker 
og brun kjøttet i små porsjoner, 2-3 minutter på sterk varme. Legg tilside. Fres grønnsakene 
i olje, ha kjøttet tilbake i woken og bland sammen. Smak til med salt og pepper, og la det 
trekke et par minutter. Server med kokt ris og chilisaus. 
Kyllingwok - 4 porsjoner 
 
- 4 stk kyllingfilet i strimler 
- 2ss olje til steking 
- 3 gulrøtter, 1 rødløk, ½ stk brokkoli, 1 pk frisk babymais, ½ pk sukkererter 
eller frossen wokblanding fra eks. Findus/Eldorado 
- Søt chilisaus, fra eks. Eldorado 
- 200g ris 
Skjær kyllingfilet i strimler. Skrell gulrot og kutt opp grønnsaker. Kok ris som anvist på 
pakken. Varm olje i en wokpanne eller en dyp stekepanne. Stek kyllingstrimlene på høy 
varme i mindre porsjoner og sett til side. Varm opp olje og fres de oppdelte grønnsaker. 
Tilsett de harde grønnsakene først og sukkererter til sist. Ha i stekt kylling. Smak evt. til 
med salt og pepper. Server med kokt ris og chilisaus. 
   
Maissuppe med sprøstekt bacon 
- 2 ss olivenolje/rapsolje 
- 1 gul løk, hakket 
- 1/2 rød paprika, hakket 
- 250 g maiskorn 
- 4 dl grønnsaksbuljong, varm 
- 2,5 dl Oatly iMat havrefløte 
- salt og nymalt hvit pepper 
- 1/2 pakke bacon, 
- litt ruccola eller bladpersille 
Varm opp oljen og fres løk og paprika i en romslig gryte uten at det tar farge. Ha i mais og 
hell i varm buljong. La det småkoke i 5 minutter. Bruk gjerne stavmikser for å få 
blandingen glatt og jevn. Ha i Oatly iMat havrefløte og smak til med salt og pepper. La alt 
bli varmt. Stek bacon sprøtt i en stekepanne og strø bacon og ruccola/bladpersille over 
suppen. Serveres med ristet, glutenfritt brød. 
 
 
Tomatsuppe med solsikkepesto 
 
Tomatsuppe 
- 1 gul løk, skåret i små biter 
- 3 hvitløksbåter, skåret i små biter 
- 1 ss olivenolje 
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- 1 boks plommetomater 
- 5 dl vann 
- 2 ss kylling eller grønnsaksfond/buljong (sjekk at den er glutenfri) 
- 1 krm salt 
- 2 krm nymalt svart pepper 
- 1 ts tørket basilikum 
- Evt. 1 ts sukker 
- 1 dl Oatly iMat havrefløte 
Solsikkepesto 
- 0,75 dl tørristede solsikkefrø 
- 1 hvitløksbåt 
- 1 potte fersk basilikum 
- 1 dl olivenolje 
- 0,5 ts fingersalt 
- 1 krm nymalt svart pepper 
 
Pesto: Miks tørristede solsikkefrø med de øvrige ingrediensene med en stavmikser. 
 
Suppe: Fres løk og hvitløk i olje i en gryte. Tilsett tomatene, vann og grønnsaks- eller 
kyllingfond. Krydre med salt, pepper, basilikum og evt sukker (kommer an på hvor søte 
tomatene er). La småkoke i 15 min under lokk. Trykk på tomatene med en sleiv, slik at de 
sprekker. Gjør suppen glatt med stavmikseren, ha i litt fløte. Kok noen minutter og smak til. 
Ha suppen i skåler, ringle i pesto. Alternativt kan suppen serveres med glutenfri makaroni 





- 1 avokado 
- 1 pk ruccola 
- 1 pk cherrytomater 
- 1 stk kyllingbryst 
- ½ - 1 rødløk 
- Kokt ris/glutenfri makaroni/pasta 
 
Forvarm ovnen til 180°C. Brun kyllingbryst på skinnsiden i varm stekepanne med olje til 
det er gyllent. Ha på salt og nykvernet sort pepper. Stek fileten videre i ovn i ca. 15 
minutter. La kyllingen hvile i 5 minutter før servering. Vask salaten. Skjær avokado i skiver 
og del cherrytomater i to. Finhakk løk og bland det med salaten. Smak til med salt og 
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Ovnsbakt kyllingfilet i bacon – 4 porsjoner 
 
- 4 stk kyllingfilet 
- 1 pk bacon 
- 4 stk potet 
- 4 stk rødbete 
- 4 stk gulrot 
- 2 stk pastinakk 
- Olje, salt og pepper 
  
Stek kyllingfiletene et par minutter i stekepannen slik at den får noe stekeskorpe. Legg 
deretter kyllingfiletene innsurret i bacon i en ildfast form. Skrell potet, rødbeter, gulrøtter 
og pastinakk og del dem i biter. Legg bitene i en ildfast form og dryss med salt, pepper og 
olje. Bak grønnsakene og kyllingen i hver sin form i ovnen. Grønnsakene skal stå i ca. 20 
minutter og kyllingen i ca. 30 minutter, begge deler ved 200 °C. 
 
Hjemmelagde hamburgere 
- 400g karbonadedeig 
- 3/4 ts salt 
- 3/4 ts finmalt pepper 
- Tørket oregano 
- Smør til steking (Soft blå) 
- Glutenfrie hamburgerbrød fra Brisk/Fria 
- Bacon 
- Isbergsalat, agurk, tomat, løk, champinjong 
Ha karbonadedeigen i en bolle sammen med krydderet. Bruk fingrene og bland alt sammen. 
Fordel deigen i 4 like store biter. Disse 4 deigbitene skal nå formes til stekeklare burgere, 
her er en enkel måte å gjøre dette på: Legg bakepapir på ei fjøl. Væt fingrene før du former 
en av deigene til en rund ball. Legg ballen på bakepapiret og press ned med håndflatene til 
denne er ca. 0,5 – 1 cm tykk. Gjenta samme prosedyre for de 3 andre deigene (væt hendene 
på nytt hver gang). Stek begge sider kjapt på høy temperatur i en stekepanne. Senk 
temperaturen og etterstek noen minutter på hver side til kjøttet er gjennomstekt. Legges på 
forvarmede, glutenfrie hamburgerbrød. Forslag til garnityr er bacon, løk, salat, agurk, 




- 3 dl appelsinjuice 
- 1 avokado 
- 1 kiwi 
- 200g frossen mango 
- Litt sitronsaft 
 
 





- 1 banan 
- 200 g blåbær (frosne, evt. frosne skogsbær) 
- 3 dl appelsinjuice 
 
 
Grønnkålsalat med quinoa, søtpoptet & eple 
 
- 3 dl tørr quinoa 
- 200 g grønnkål (5 store blader) 
- 2 røde epler (gjerne crispy pink lady) 
- 2 søtpoteter 
- Olivenolje 
Dressing: 
- saften av 1/2 sitron 
- 2 ss dijonsennep 
- 2 ss rødvinseddik 
- 4 ss olivenolje 
- 1 ts honning 
- salt + pepper 
Kok quinoa etter anvisning på pakken, 1 del quinoa til 2 deler vann. Skrell søtpotet og 
skjær dem i små terninger. Ovnsbak søtpotet med et dryss av olivenolje, salt og pepper i ca 
20 min, til bitene er møre. Finkakk grønnkål, og skjær eplene i tynne skiver. Bland sammen 
alle ingrediensene til dressingen. Vend sammen quinoa, grønnkål, eplebiter og ovnsbakt 
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Appendix 9: Compliance questionnaire 3 weeks 
 
Overholdelse av eliminasjonsdietten 3 uker ut i diettbehandlingen 
 
Vennligst sett strek på tvers eller kryss tydelig av. 
 
Har du fulgt dietten de siste 3 ukene? 
 Ja 
 Delvis 





Hvordan synes du det var å følge dietten: 
 
Kjempelett          Veldig utfordrende 
            





Hvor nøye har du fulgt eliminasjonsdietten gjennom de siste 3 ukene? 
 
Ikke fulgt den i det hele tatt                        Kun spist etter dietten                                                                                                                                                                       
  





Hvor fornøyd er du med eliminasjonsdietten som symptomlindring?  
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Svært misfornøyd                                                                         Svært fornøyd 
 





Hvis du er misfornøyd med dietten, hvorfor: 
 For tidkrevende 
 Savner for mange matvarer 
 Opplever ingen bedring 
 For dyrt  
 Dietten er kjedelig mtp. smak/variasjon e.l. 






Hvor ofte hadde du avvik fra dietten i løpet av de 3 ukene: 
 Ingen ganger 
 1-2 ganger i løpet av de 3 ukene 
 1-2 ganger i uken 




Hva slags type matvarer inntok du ved avvik fra dietten? 










Hvorfor spiste du mat som ikke inngår i eliminasjonsdietten: 
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 Fulgt kun eliminasjonsdietten 
 Visste ikke at maten inneholdt en av de eliminerte matvarene 
 Ikke tilgang på maten som inngår i eliminasjonsdietten på restaurant/gatekjøkken 
 For tidkrevende å lage mat etter eliminasjonsdietten 
 Merket ikke noe effekt av dietten og dermed stoppet jeg 
 Hadde lyst på matvarer som ikke inngår i eliminasjonsdietten 




Hvor lenge gikk du på dietten før du spiste matvarer som ikke inngår i dietten: 
 Jeg gikk på dietten hele tiden 
 Ingen dager 
 1-3 dager 
 4-7 dager 




Hvor fornøyd er du med informasjonen du fikk om dietten: 




 Meget fornøyd  
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Appendix 10: Compliance questionnaire 6 weeks 
 
Overholdelse av eliminasjonsdietten etter 6 uker 
 
Vennligst sett strek på tvers eller kryss tydelig av. 
 
Har du fulgt dietten de siste 6 ukene? 
 Ja 
 Delvis 





Hvordan synes du det var å følge dietten: 
 
Kjempelett                                                                                         Meget vanskelig 
 





Hvor nøye har du fulgt eliminasjonsdietten gjennom de siste 6 ukene? 
 
Ikke fulgt den i det hele tatt                      Kun spist etter dietten                                                                                                                                                                       
  





Hvor fornøyd er du med eliminasjonsdietten som symptomlindring?  
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Svært misfornøyd                                                                         Svært fornøyd 
 




Hvis du er misfornøyd med dietten, hvorfor: 
 For tidkrevende 
 Savner for mange matvarer 
 Opplever ingen bedring 
 For dyrt  
 Dietten er kjedelig mtp. smak/variasjon e.l. 






Hvor ofte hadde du avvik fra dietten løpet av de siste 6 ukene: 
 Ingen ganger 
 1-5 ganger i løpet av de 6 ukene 
 1-2 ganger i uken 




Hva slags type matvarer inntok du ved avvik fra dietten? 










Hvorfor spiste du mat som ikke inngår i eliminasjonsdietten: 
 Fulgt kun eliminasjonsdietten 
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 Visste ikke at maten inneholdt en av de eliminerte matvarene 
 Ikke tilgang på maten som inngår i eliminasjonsdietten på restaurant/gatekjøkken 
 For tidkrevende å lage mat etter eliminasjonsdietten 
 Merket ikke noe effekt av dietten og dermed stoppet jeg 
 Hadde lyst på matvarer som ikke inngår i eliminasjonsdietten 




Hvor lenge gikk du på dietten før du spiste matvarer som ikke inngår i dietten: 
 Jeg gikk på dietten hele tiden 
 Ingen dager 
 1-3 dager 
 4-7 dager 
 2-3 uker 
 3-4 uker 




Hvor fornøyd er du med informasjonen du fikk om dietten: 
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Appendix 11: The Chicago Classification of esophageal motility version 3.0. Reused with 
permission from John Wiley and Sons.  
ACHALASIA and EGJ 
OUTFLOW OBSTRUCTION 
CRITERIA 
Type I achalasia (classic 
achalasia) 
Elevated median IRP (>15 mmHg†), 100% failed peristalsis 
(DCI <100 mmHg) 
Premature contractions with DCI values less than 
450 mmHg·s·cm satisfy criteria for failed peristalsis 
Type II achalasia (with 
esophageal compression) 
Elevated median IRP (>15 mmHg†), 100% failed peristalsis, 
panesophageal pressurization with ≥20% of swallows 
Contractions may be masked by esophageal pressurization and DCI 
should not be calculated 
Type III achalasia (spastic 
achalasia) 
Elevated median IRP (>15 mmHg†), no normal peristalsis, premature 
(spastic) contractions with DCI >450 mmHg·s·cm with ≥20% of 
swallows 
May be mixed with panesophageal pressurization 
EGJ outflow obstruction Elevated median IRP (>15 mmHg†), sufficient evidence of peristalsis 
such that criteria for types I-III achalasia are not met* 
MAJOR DISORDERS of 
PERISTALSIS 
(Not encountered in normal subjects) 
Absent contractility Normal median IRP, 100% failed peristalsis 
Achalasia should be considered when IRP values are borderline and 
when there is evidence of esophageal pressurization 
Premature contractions with DCI values less than 
450 mmHg·s·cm meet criteria for failed peristalsis 
Distal esophageal spasm Normal median IRP, ≥20% premature contractions with DCI >450 
mmHg·s·cm †. Some normal peristalsis may be present. 
Hypercontractile esophagus 
(jackhammer) 
At least two swallows with DCI >8,000 mmHg·s·cm †§ 
Hypercontractility may involve, or even be localized to, the LES 
MINOR DISORDERS OF 
PERISTALSIS 
(Characterized by contractile vigor and contraction pattern) 
Ineffective esophageal motility  
(IEM) 
≥50% ineffective swallows 
 
Ineffective swallows can be failed or weak (DCI<450 mmHg·s·cm) 
Multiple repetitive swallow assessment may be helpful in determining 
peristaltic reserve 
Fragmented peristalsis ≥50% fragmented contractions with DCI > 450 mmHg·s·cm 




†Cutoff value dependent on the manometric hardware; this is the cutoff for the Sierra device 
*Potential etiologies: early achalasia, mechanical obstruction, esophageal wall stiffness, or manifestation of hiatal 
hernia 
§Hypercontractile esophagus can be a manifestation of outflow obstruction as evident by instances in which it 




Not fulfilling any of the above classifications 
